{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:58:05Z","timestamp":1793228285990,"version":"4.5.0"},"reference-count":296,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01851-4","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:53:05Z","timestamp":1770835985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications"],"prefix":"10.1007","volume":"26","author":[{"given":"Xiaodong","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hechen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"8","key":"1851_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"Y-C Hsu","year":"2023","unstructured":"Hsu Y-C, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(8):524\u201337.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1851_CR2","doi-asserted-by":"crossref","unstructured":"Mak, D.; Kramvis, A. Epidemiology and aetiology of hepatocellular carcinoma in Sub-Saharan Africa. Hepatoma Research 2021, 7, N\/A-N\/A.","DOI":"10.20517\/2394-5079.2021.15"},{"issue":"9","key":"1851_CR3","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/liv.15251","volume":"42","author":"Ch Zhang","year":"2022","unstructured":"Zhang Ch, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2029\u201341.","journal-title":"Liver Int"},{"key":"1851_CR4","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S307962","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Han Q, Zhao H, Zhang J. The mechanisms of HBV-induced hepatocellular carcinoma. J Hepatocell Carcinoma. 2021. https:\/\/doi.org\/10.2147\/JHC.S307962.","journal-title":"J Hepatocell Carcinoma"},{"key":"1851_CR5","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3389\/fimmu.2019.02048","volume":"10","author":"Y Chen","year":"2019","unstructured":"Chen Y, Tian Z. HBV-induced immune imbalance in the development of HCC. Front Immunol. 2019;10:2048.","journal-title":"Front Immunol"},{"key":"1851_CR6","doi-asserted-by":"crossref","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 2022;9(2).","DOI":"10.1016\/S2215-0366(21)00395-3"},{"issue":"21","key":"1851_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033666","volume":"102","author":"NS Zhang","year":"2023","unstructured":"Zhang NS, Wong RJ. Geographical disparities in hepatitis b virus related hepatocellular carcinoma mortality rates worldwide from 1990 to 2019. Medicine. 2023;102(21): e33666.","journal-title":"Medicine"},{"issue":"2","key":"1851_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/hep.30833","volume":"71","author":"GLH Wong","year":"2020","unstructured":"Wong GLH, Wong VWS, Yuen BWY, Tse YK, Luk HWS, Yip TCF, Hui VWK, Liang LY, Lui GCY, Chan HLY. An aging population of chronic hepatitis B with increasing comorbidities: a territory-wide study from 2000 to 2017. Hepatology. 2020;71(2):444\u201355.","journal-title":"Hepatology"},{"key":"1851_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s11901-019-00478-w","volume":"18","author":"S Nayagam","year":"2019","unstructured":"Nayagam S, Thursz M. Strategies for global elimination of chronic HBV infection: 2019 update. Curr Hepatol Rep. 2019;18:300\u20139.","journal-title":"Curr Hepatol Rep"},{"issue":"1","key":"1851_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cld.733","volume":"12","author":"BJ McMahon","year":"2018","unstructured":"McMahon BJ. Meeting the WHO and US goals to eliminate hepatitis B infection by 2030: opportunities and challenges. Clin Liver Dis. 2018;12(1):29\u201332.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"1851_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-virology-110615-042238","volume":"3","author":"B Venkatakrishnan","year":"2016","unstructured":"Venkatakrishnan B, Zlotnick A. The structural biology of hepatitis B virus: form and function. Annu Rev Virol. 2016;3(1):429\u201351.","journal-title":"Annu Rev Virol"},{"issue":"1","key":"1851_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41421-024-00768-8","volume":"11","author":"X He","year":"2025","unstructured":"He X, Kang Y, Tao W, Xu J, Liu X, Chen L. Structure of small HBV surface antigen reveals mechanism of dimer formation. Cell Discovery. 2025;11(1):6.","journal-title":"Cell Discovery"},{"issue":"4","key":"1851_CR13","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.7150\/ijbs.55724","volume":"17","author":"X Jiang","year":"2021","unstructured":"Jiang X, Chang L, Yan Y, Wang L. Paradoxical HBsAg and anti-HBs coexistence among chronic HBV infections: causes and consequences. Int J Biol Sci. 2021;17(4):1125.","journal-title":"Int J Biol Sci"},{"key":"1851_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101360","volume":"63","author":"N Nasser","year":"2023","unstructured":"Nasser N, Tonnerre P, Mansouri A, Asselah T. Hepatitis-B virus: replication cycle, targets, and antiviral approaches. Curr Opin Virol. 2023;63: 101360.","journal-title":"Curr Opin Virol"},{"key":"1851_CR15","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S480151","author":"S Li","year":"2024","unstructured":"Li S, Hao L, Deng J, Zhang J, Yu F, Ye F, Li N, Hu X. The culprit behind HBV-infected hepatocytes: NTCP. Drug Des Devel Ther. 2024. https:\/\/doi.org\/10.2147\/DDDT.S480151.","journal-title":"Drug Des Devel Ther"},{"issue":"7916","key":"1851_CR16","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41586-022-04857-0","volume":"606","author":"J-H Park","year":"2022","unstructured":"Park J-H, Iwamoto M, Yun J-H, Uchikubo-Kamo T, Son D, Jin Z, Yoshida H, Ohki M, Ishimoto N, Mizutani K. Structural insights into the HBV receptor and bile acid transporter NTCP. Nature. 2022;606(7916):1027\u201331.","journal-title":"Nature"},{"issue":"8","key":"1851_CR17","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3390\/v13081463","volume":"13","author":"L Wei","year":"2021","unstructured":"Wei L, Ploss A. Mechanism of hepatitis B virus cccDNA formation. Viruses. 2021;13(8):1463.","journal-title":"Viruses"},{"issue":"1","key":"1851_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40364-024-00611-y","volume":"12","author":"M Zhang","year":"2024","unstructured":"Zhang M, Chen H, Liu H, Tang H. The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy. Biomark Res. 2024;12(1):84.","journal-title":"Biomark Res"},{"issue":"4","key":"1851_CR19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","volume":"75","author":"M-A Meier","year":"2021","unstructured":"Meier M-A, Calabrese D, Suslov A, Terracciano LM, Heim MH, Wieland S. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol. 2021;75(4):840\u20137.","journal-title":"J Hepatol"},{"issue":"2","key":"1851_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100398","volume":"4","author":"T Vanwolleghem","year":"2022","unstructured":"Vanwolleghem T, Adomati T, Van Hees S, Janssen HL. Humoral immunity in hepatitis B virus infection: rehabilitating the B in HBV. JHEP Reports. 2022;4(2): 100398.","journal-title":"JHEP Reports"},{"issue":"11","key":"1851_CR21","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1136\/gutjnl-2021-324646","volume":"71","author":"E Aliabadi","year":"2022","unstructured":"Aliabadi E, Urbanek-Quaing M, Maasoumy B, Bremer B, Grasshoff M, Li Y, Niehaus CE, Wedemeyer H, Kraft AR, Cornberg M. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut. 2022;71(11):2300\u201312.","journal-title":"Gut"},{"key":"1851_CR22","doi-asserted-by":"crossref","unstructured":"Lyu, X.; Sze, K. M.-F.; Lee, J. M.-F.; Husain, A.; Tian, L.; Imbeaud, S.; Zucman-Rossi, J.; Ng, I. O.-L.; Ho, D. W.-H. Disparity landscapes of viral-induced structural variations in HCC: mechanistic characterization and functional implications. Hepatology 2024;10.1097.","DOI":"10.1097\/HEP.0000000000001087"},{"issue":"2","key":"1851_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/microorganisms10020253","volume":"10","author":"M Bousali","year":"2022","unstructured":"Bousali M, Karamitros T. Hepatitis B virus integration into transcriptionally active loci and HBV-associated hepatocellular carcinoma. Microorganisms. 2022;10(2):253.","journal-title":"Microorganisms"},{"issue":"1","key":"1851_CR24","first-page":"2140886","volume":"2022","author":"G Wang","year":"2022","unstructured":"Wang G, Chen Z. HBV genomic integration and hepatocellular carcinoma. Adv  Gut Microbiome Res. 2022;2022(1):2140886.","journal-title":"Adv Gut Microbiome Res"},{"issue":"3","key":"1851_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ccr.2014.01.030","volume":"25","author":"C-C Lau","year":"2014","unstructured":"Lau C-C, Sun T, Ching AK, He M, Li J-W, Wong AM, Chan AW, Li P-S, Lung RW, Tong JH. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell. 2014;25(3):335\u201349.","journal-title":"Cancer Cell"},{"issue":"6","key":"1851_CR26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41388-020-01593-5","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yan Q, Gong L, Xu H, Liu B, Fang X, Yu D, Li L, Wei T, Wang Y. C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism. Oncogene. 2021;40(6):1147\u201361.","journal-title":"Oncogene"},{"key":"1851_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.105136","volume":"159","author":"C Zhang","year":"2021","unstructured":"Zhang C, Xiao C, Ren G, Cai D, Long L, Li J, Li K, Tang Y, Huang T, Deng W. C-terminal-truncated hepatitis B virus X protein promotes hepatocarcinogenesis by activating the MAPK pathway. Microb Pathog. 2021;159: 105136.","journal-title":"Microb Pathog"},{"issue":"4","key":"1851_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/cells11040741","volume":"11","author":"E Sivasudhan","year":"2022","unstructured":"Sivasudhan E, Blake N, Lu Z, Meng J, Rong R. Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review. Cells. 2022;11(4):741.","journal-title":"Cells"},{"issue":"24","key":"1851_CR29","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.18632\/oncotarget.28077","volume":"12","author":"A Medhat","year":"2021","unstructured":"Medhat A, Arzumanyan A, Feitelson MA. Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma. Oncotarget. 2021;12(24):2421.","journal-title":"Oncotarget"},{"issue":"5","key":"1851_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/v14050986","volume":"14","author":"GEM Rizzo","year":"2022","unstructured":"Rizzo GEM, Cabibbo G, Crax\u00ec A. Hepatitis B virus-associated hepatocellular carcinoma. Viruses. 2022;14(5):986.","journal-title":"Viruses"},{"issue":"2","key":"1851_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.26502\/jcsct.5079158","volume":"6","author":"X Zhou","year":"2022","unstructured":"Zhou X, Liu D, Li Z, Zhao J, Cai S, Cao G. The mechanism of hepatitis B virus X gene in promoting hepatocellular carcinoma. J Cancer Sci Clin Ther. 2022;6(2):222\u201333.","journal-title":"J Cancer Sci Clin Ther"},{"issue":"4","key":"1851_CR32","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12072-022-10351-6","volume":"16","author":"L Yang","year":"2022","unstructured":"Yang L, Zou T, Chen Y, Zhao Y, Wu X, Li M, Du F, Chen Y, Xiao Z, Shen J. Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma. Hepatol Int. 2022;16(4):741\u201354.","journal-title":"Hepatol Int"},{"issue":"13","key":"1851_CR33","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.3390\/cancers13133115","volume":"13","author":"V Alfano","year":"2021","unstructured":"Alfano V, Zeisel MB, Levrero M, Guerrieri F. The lncRNAs in HBV-related HCCs: targeting chromatin dynamics and beyond. Cancers. 2021;13(13):3115.","journal-title":"Cancers"},{"issue":"7","key":"1851_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102180","volume":"47","author":"J Chen","year":"2023","unstructured":"Chen J, Li L, Yin Q, Shen T. A review of epidemiology and clinical relevance of hepatitis B virus genotypes and subgenotypes. Clin Res Hepatol Gastroenterol. 2023;47(7): 102180.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"1851_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.31557\/APJCP.2024.25.2.371","volume":"25","author":"K Changsri","year":"2024","unstructured":"Changsri K, Duangchanda T, Soimanee T, Fuckpo W, Pipatsatitpong D, Akekawatchai C. Distribution and clinical significance of hepatitis B virus A1762T\/G1764A double mutation in chronic hepatitis B patients: a cross-sectional study. Asian Pacific J  Cancer Prevent APJCP. 2024;25(2):371.","journal-title":"Asian Pacific J Cancer Prevent APJCP"},{"issue":"5","key":"1851_CR36","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.virs.2023.06.004","volume":"38","author":"B Zhao","year":"2023","unstructured":"Zhao B, Qiao H, Zhao Y, Gao Z, Wang W, Cui Y, Li J, Guo Z, Chuai X, Chiu S. HBV precore G1896A mutation promotes growth of hepatocellular carcinoma cells by activating ERK\/MAPK pathway. Virol Sin. 2023;38(5):680\u20139.","journal-title":"Virol Sin"},{"issue":"3","key":"1851_CR37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hep.32802","volume":"78","author":"YK Lam","year":"2023","unstructured":"Lam YK, Yu J, Huang H, Ding X, Wong AM, Leung HH, Chan AW, Ng KK, Xu M, Wang X. TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk. Hepatology. 2023;78(3):727\u201340.","journal-title":"Hepatology"},{"issue":"3","key":"1851_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00251-021-01213-w","volume":"73","author":"G Ou","year":"2021","unstructured":"Ou G, Liu X, Xu H, Ji X, Liu X, Wang J. Variation and expression of HLA-DPB1 gene in HBV infection. Immunogenetics. 2021;73(3):253\u201361.","journal-title":"Immunogenetics"},{"issue":"2","key":"1851_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.14044","volume":"32","author":"X Tan","year":"2025","unstructured":"Tan X, Xun L, Yin Q, Chen C, Zhang T, Shen T. Epigenetic modifications in HBV-related hepatocellular carcinoma. J Viral Hepat. 2025;32(2): e14044.","journal-title":"J Viral Hepat"},{"issue":"2","key":"1851_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/hep.31313","volume":"73","author":"GW Kim","year":"2021","unstructured":"Kim GW, Imam H, Khan M, Mir SA, Kim SJ, Yoon SK, Hur W, Siddiqui A. HBV-induced increased N6 methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC. Hepatology. 2021;73(2):533\u201347.","journal-title":"Hepatology"},{"issue":"3","key":"1851_CR41","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/ijms24032652","volume":"24","author":"L-Y Tian","year":"2023","unstructured":"Tian L-Y, Smit DJ, J\u00fccker M. The role of PI3K\/AKT\/mTOR signaling in hepatocellular carcinoma metabolism. Int J Mol Sci. 2023;24(3):2652.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1851_CR42","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1111\/jgh.15999","volume":"37","author":"C Zhang","year":"2022","unstructured":"Zhang C, Dai D, Zhang W, Yang W, Guo Y, Wei Q. Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2022;37(11):2039\u201350.","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"1851_CR43","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/jcm10081715","volume":"10","author":"MB Zeisel","year":"2021","unstructured":"Zeisel MB, Guerrieri F, Levrero M. Host epigenetic alterations and hepatitis B virus-associated hepatocellular carcinoma. J Clin Med. 2021;10(8):1715.","journal-title":"J Clin Med"},{"key":"1851_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661204","volume":"12","author":"K Sartorius","year":"2021","unstructured":"Sartorius K, An P, Winkler C, Chuturgoon A, Li X, Makarova J, Kramvis A. The epigenetic modulation of cancer and immune pathways in hepatitis B virus-associated hepatocellular carcinoma: the influence of HBx and miRNA dysregulation. Front Immunol. 2021;12: 661204.","journal-title":"Front Immunol"},{"issue":"11","key":"1851_CR45","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/jgh.16340","volume":"38","author":"H Wang","year":"2023","unstructured":"Wang H, Zhang J. The glucose metabolic reprogramming in hepatitis B virus infection and hepatitis B virus associated diseases. J Gastroenterol Hepatol. 2023;38(11):1886\u201391.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"1851_CR46","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12876-023-03026-5","volume":"23","author":"P Yan","year":"2023","unstructured":"Yan P, Luo Y, Huang Z, Mou T, Yang H, Peng D, Wu Z. Establishment of a prognostic signature based on fatty acid metabolism genes in HCC associated with hepatitis B. BMC Gastroenterol. 2023;23(1):390.","journal-title":"BMC Gastroenterol"},{"key":"1851_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.762828","volume":"9","author":"F Zhou","year":"2021","unstructured":"Zhou F, Sun X. Cholesterol metabolism: a double-edged sword in hepatocellular carcinoma. Front Cell Dev Biol. 2021;9: 762828.","journal-title":"Front Cell Dev Biol"},{"key":"1851_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217061","author":"L-Q Cao","year":"2024","unstructured":"Cao L-Q, Xie Y, Fleishman JS, Liu X, Chen Z-S. Hepatocellular carcinoma and lipid metabolism: novel targets and therapeutic strategies. Cancer Lett. 2024. https:\/\/doi.org\/10.1016\/j.canlet.2024.217061.","journal-title":"Cancer Lett"},{"key":"1851_CR49","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.18632\/oncotarget.28306","volume":"13","author":"Y Morine","year":"2022","unstructured":"Morine Y, Utsunomiya T, Yamanaka-Okumura H, Saito Y, Yamada S, Ikemoto T, Imura S, Kinoshita S, Hirayama A, Tanaka Y. Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis. Oncotarget. 2022;13:1286.","journal-title":"Oncotarget"},{"issue":"7","key":"1851_CR50","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/onc.2013.236","volume":"33","author":"L Liu","year":"2014","unstructured":"Liu L, Dong Z, Liang J, Cao C, Sun J, Ding Y, Wu D. As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt\/GSK3\u03b2 pathway. Oncogene. 2014;33(7):909\u201320.","journal-title":"Oncogene"},{"issue":"11","key":"1851_CR51","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/biomedicines9111639","volume":"9","author":"EJ Sun","year":"2021","unstructured":"Sun EJ, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Targeting the PI3K\/Akt\/mTOR pathway in hepatocellular carcinoma. Biomedicines. 2021;9(11):1639.","journal-title":"Biomedicines"},{"issue":"12","key":"1851_CR52","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.3390\/cancers13123026","volume":"13","author":"H Moon","year":"2021","unstructured":"Moon H, Ro SW. MAPK\/ERK signaling pathway in hepatocellular carcinoma. Cancers (Basel). 2021;13(12):3026.","journal-title":"Cancers (Basel)"},{"issue":"18","key":"1851_CR53","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.3390\/ijms20184659","volume":"20","author":"D Bender","year":"2019","unstructured":"Bender D, Hildt E. Effect of hepatitis viruses on the Nrf2\/Keap1-signaling pathway and its impact on viral replication and pathogenesis. Int J Mol Sci. 2019;20(18):4659.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1851_CR54","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/jcm10050991","volume":"10","author":"M Hofmann","year":"2021","unstructured":"Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T cell responses during HCV infection and HCC. J Clin Med. 2021;10(5):991.","journal-title":"J Clin Med"},{"issue":"1","key":"1851_CR55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"key":"1851_CR56","doi-asserted-by":"crossref","unstructured":"Arvanitakis K, Papadakos SP, Vakadaris G, Chatzikalil E, Stergiou IE, Kalopitas G, Theocharis S, Germanidis G. Shedding light on the role of LAG-3 in hepatocellular carcinoma: Unraveling immunomodulatory pathways. Hepatoma Rese 2024;10","DOI":"10.20517\/2394-5079.2024.36"},{"key":"1851_CR57","doi-asserted-by":"publisher","first-page":"205031212110690","DOI":"10.1177\/20503121211069012","volume":"10","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar B. Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med. 2022;10:20503121211069012.","journal-title":"SAGE Open Med"},{"key":"1851_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.729705","volume":"12","author":"X Zheng","year":"2021","unstructured":"Zheng X, Jin W, Wang S, Ding H. Progression on the roles and mechanisms of tumor-infiltrating T lymphocytes in patients with hepatocellular carcinoma. Front Immunol. 2021;12: 729705.","journal-title":"Front Immunol"},{"issue":"5","key":"1851_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29627","volume":"96","author":"L Wu","year":"2024","unstructured":"Wu L, Deng H, Feng X, Xie D, Li Z, Chen J, Mo Z, Zhao Q, Hu Z, Yi S. Interferon-\u03b3+ Th1 activates intrahepatic resident memory T cells to promote HBsAg loss by inducing M1 macrophage polarization. J Med Virol. 2024;96(5): e29627.","journal-title":"J Med Virol"},{"issue":"22","key":"1851_CR60","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.3748\/wjg.v27.i22.2994","volume":"27","author":"A Granito","year":"2021","unstructured":"Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol. 2021;27(22):2994.","journal-title":"World J Gastroenterol"},{"issue":"27","key":"1851_CR61","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3748\/wjg.v28.i27.3346","volume":"28","author":"C-Y Zhang","year":"2022","unstructured":"Zhang C-Y, Liu S, Yang M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J Gastroenterol. 2022;28(27):3346.","journal-title":"World J Gastroenterol"},{"key":"1851_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599648","volume":"11","author":"A Khanam","year":"2021","unstructured":"Khanam A, Ayithan N, Tang L, Poonia B, Kottilil S. IL-21\u2013deficient T follicular helper cells support B cell responses through IL-27 in patients with chronic hepatitis B. Front Immunol. 2021;11: 599648.","journal-title":"Front Immunol"},{"issue":"1","key":"1851_CR63","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","volume":"9","author":"W Zhu","year":"2024","unstructured":"Zhu W, Zhang Z, Chen J, Chen X, Huang L, Zhang X, Huang X, Ma N, Xu W, Yi X. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma. Signal Transduct Target Ther. 2024;9(1):101.","journal-title":"Signal Transduct Target Ther"},{"key":"1851_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887186","volume":"13","author":"M Sajid","year":"2022","unstructured":"Sajid M, Liu L, Sun C. The dynamic role of NK cells in liver cancers: role in HCC and HBV associated HCC and its therapeutic implications. Front Immunol. 2022;13: 887186.","journal-title":"Front Immunol"},{"issue":"3","key":"1851_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2024.110775","volume":"85","author":"Y Ma","year":"2024","unstructured":"Ma Y, Ping D, Huang K, Tao Y, Peng Y, Sun X, Liu C. Lower NKG2D expression in hepatic natural killer cells predicts poorer prognosis for chronic hepatitis B patients with cirrhosis. Hum Immunol. 2024;85(3): 110775.","journal-title":"Hum Immunol"},{"key":"1851_CR66","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.imlet.2023.04.009","volume":"258","author":"X Guan","year":"2023","unstructured":"Guan X, Lu Y, Zhang Y, Zhan P, Chen Z, Wang C, Yin Z. Tumor-associated NK cells facilitate tumor growth via NKp46 in immunocompetent murine hepatocellular carcinoma. Immunol Lett. 2023;258:8\u201319.","journal-title":"Immunol Lett"},{"key":"1851_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-024-09495-4","author":"X Wu","year":"2024","unstructured":"Wu X, Zhao W, Miao Q, Shi S, Wei B, Luo L, Cai B. Ccr2+ TREM-1+ monocytes promote natural killer T cell dysfunction contributing towards HBV disease progression. Immunol Res. 2024. https:\/\/doi.org\/10.1007\/s12026-024-09495-4.","journal-title":"Immunol Res"},{"key":"1851_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693076","volume":"11","author":"M Mehrabi","year":"2021","unstructured":"Mehrabi M, Amini F, Mehrabi S. Kill and clearance in HCC: an approach based on NK cells and macrophages. Front Oncol. 2021;11: 693076.","journal-title":"Front Oncol"},{"key":"1851_CR69","doi-asserted-by":"crossref","unstructured":"Wang X, Yang T, Shi X. NK cell-based immunotherapy in hepatocellular carcinoma: an attractive therapeutic option for the next decade. Cellular Signal 2024;111405.","DOI":"10.1016\/j.cellsig.2024.111405"},{"issue":"5","key":"1851_CR70","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/hep.31792","volume":"73","author":"M Song","year":"2021","unstructured":"Song M, He J, Pan QZ, Yang J, Zhao J, Zhang YJ, Huang Y, Tang Y, Wang Q, He J. Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression. Hepatology. 2021;73(5):1717\u201335.","journal-title":"Hepatology"},{"key":"1851_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109193","volume":"112","author":"J Wang","year":"2022","unstructured":"Wang J, Liu X, Jin T, Cao Y, Tian Y, Xu F. NK cell immunometabolism as target for liver cancer therapy. Int Immunopharmacol. 2022;112: 109193.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"1851_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101189","volume":"6","author":"N Petriv","year":"2024","unstructured":"Petriv N, Suo H, Hochnadel I, Timrott K, Bondarenko N, Neubert L, Reinhard E, Jedicke N, Kaufhold P, Guzm\u00e1n CA. Essential roles of B cell subsets in the progression of MASLD and HCC. JHEP Rep. 2024;6(12): 101189.","journal-title":"JHEP Rep"},{"issue":"2","key":"1851_CR73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3892\/or.2021.8249","volume":"47","author":"Y Feng","year":"2022","unstructured":"Feng Y, Liu L, Li J, Huang J, Xie JH, Menard L, Shi Y, Zhao X, Xie S, Zang W. Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target. Oncol Rep. 2022;47(2):38.","journal-title":"Oncol Rep"},{"issue":"24","key":"1851_CR74","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.1158\/1078-0432.CCR-24-0479","volume":"30","author":"Y Kurebayashi","year":"2024","unstructured":"Kurebayashi Y, Sugimoto K, Tsujikawa H, Matsuda K, Nomura R, Ueno A, Masugi Y, Yamazaki K, Effendi K, Takeuchi H. Spatial dynamics of T-and B-cell responses predicts clinical outcome of resectable and unresectable hepatocellular carcinoma. Clin Cancer Res. 2024;30(24):5666\u201380.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1851_CR75","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman WH, Meylan M, Petitprez F, Sun C-M, Italiano A, Saut\u00e8s-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19(7):441\u201357.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1851_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2024.152842","volume":"229","author":"M Qin","year":"2024","unstructured":"Qin M, Chen Y, Wang X, Zhang X, Pan X. Dexmedetomidine induces IL-10 secretion by B lymphocytes in the peripheral blood of patients with hepatocellular carcinoma. Immunobiology. 2024;229(5): 152842.","journal-title":"Immunobiology"},{"key":"1851_CR77","doi-asserted-by":"publisher","first-page":"1506526","DOI":"10.3389\/fimmu.2025.1506526","volume":"16","author":"H Zheng","year":"2025","unstructured":"Zheng H, Xu B, Fan Y, Tuekprakhon A, Stamataki Z, Wang F. The role of immune regulation in HBV infection and hepatocellular carcinogenesis. Front Immunol. 2025;16:1506526.","journal-title":"Front Immunol"},{"issue":"1","key":"1851_CR78","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/cancers14010226","volume":"14","author":"K Arvanitakis","year":"2022","unstructured":"Arvanitakis K, Koletsa T, Mitroulis I, Germanidis G. Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy. Cancers. 2022;14(1):226.","journal-title":"Cancers"},{"issue":"1","key":"1851_CR79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41420-023-01356-7","volume":"9","author":"H Zheng","year":"2023","unstructured":"Zheng H, Peng X, Yang S, Li X, Huang M, Wei S, Zhang S, He G, Liu J, Fan Q. Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy. Cell Death Discov. 2023;9(1):65.","journal-title":"Cell Death Discov"},{"issue":"5","key":"1851_CR80","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.7150\/jca.51346","volume":"12","author":"Y Huang","year":"2021","unstructured":"Huang Y, Ge W, Zhou J, Gao B, Qian X, Wang W. The role of tumor associated macrophages in hepatocellular carcinoma. J Cancer. 2021;12(5):1284.","journal-title":"J Cancer"},{"issue":"5","key":"1851_CR81","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s10238-022-00888-z","volume":"23","author":"R Qin","year":"2023","unstructured":"Qin R, Ren W, Ya G, Wang B, He J, Ren S, Jiang L, Zhao S. Role of chemokines in the crosstalk between tumor and tumor-associated macrophages. Clin Exp Med. 2023;23(5):1359\u201373.","journal-title":"Clin Exp Med"},{"key":"1851_CR82","doi-asserted-by":"publisher","first-page":"1429812","DOI":"10.3389\/fimmu.2024.1429812","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Han G, Gu J, Chen Z, Wu J. Role of tumor-associated macrophages in hepatocellular carcinoma: impact, mechanism, and therapy. Front Immunol. 2024;15:1429812.","journal-title":"Front Immunol"},{"key":"1851_CR83","doi-asserted-by":"publisher","first-page":"1472430","DOI":"10.3389\/fimmu.2024.1472430","volume":"15","author":"MN Khan","year":"2024","unstructured":"Khan MN, Mao B, Hu J, Shi M, Wang S, Rehman AU, Li X. Tumor-associated macrophages and CD8+ T cells: dual players in the pathogenesis of HBV-related HCC. Front Immunol. 2024;15:1472430.","journal-title":"Front Immunol"},{"issue":"24","key":"1851_CR84","doi-asserted-by":"publisher","first-page":"22109","DOI":"10.1002\/cam4.6717","volume":"12","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yu C, Zhao S, Wang M, Shang L, Zhou J, Ma Y. The role of tumor-associated macrophages in hepatocellular carcinoma progression: a narrative review. Cancer Med. 2023;12(24):22109\u201329.","journal-title":"Cancer Med"},{"key":"1851_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01207-x","volume":"14","author":"J-C Lu","year":"2021","unstructured":"Lu J-C, Zhang P-F, Huang X-Y, Guo X-J, Gao C, Zeng H-Y, Zheng Y-M, Wang S-W, Cai J-B, Sun Q-M. Amplification of spatially isolated adenosine pathway by tumor\u2013macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. J Hematol Oncol. 2021;14:1\u201320.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1851_CR86","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jhep.2020.10.021","volume":"74","author":"J Wang","year":"2021","unstructured":"Wang J, Wang Y, Chu Y, Li Z, Yu X, Huang Z, Xu J, Zheng L. Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma. J Hepatol. 2021;74(3):627\u201337.","journal-title":"J Hepatol"},{"issue":"9","key":"1851_CR87","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00262-024-03748-9","volume":"73","author":"Q Xie","year":"2024","unstructured":"Xie Q, Zeng Y, Zhang X, Yu F. The significance of lipid metabolism reprogramming of tumor-associated macrophages in hepatocellular carcinoma. Cancer Immunol Immunother. 2024;73(9):171.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1851_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02567-z","volume":"42","author":"Y Li","year":"2023","unstructured":"Li Y, Yang W, Zheng Y, Dai W, Ji J, Wu L, Cheng Z, Zhang J, Li J, Xu X. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. J Exp Clin Cancer Res. 2023;42(1): 6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1851_CR89","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1186\/s12967-023-04716-0","volume":"21","author":"J Huang","year":"2023","unstructured":"Huang J, Wu Q, Geller DA, Yan Y. Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC). J Transl Med. 2023;21(1):815.","journal-title":"J Transl Med"},{"issue":"1","key":"1851_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02170-7","volume":"23","author":"X Liu","year":"2025","unstructured":"Liu X, Kang X, Kang H, Yan H. The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities. Cell Commun Signal. 2025;23(1): 155.","journal-title":"Cell Commun Signal"},{"issue":"2","key":"1851_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12020299","volume":"12","author":"C Zhang","year":"2024","unstructured":"Zhang C, Sui Y, Liu S, Yang M. The roles of myeloid-derived suppressor cells in liver disease. Biomedicines. 2024;12(2): 299.","journal-title":"Biomedicines"},{"key":"1851_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100788","volume":"28","author":"X Deng","year":"2022","unstructured":"Deng X, Li X, Guo X, Lu Y, Xie Y, Huang X, Lin J, Tan W, Wang C. Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis. Neoplasia. 2022;28: 100788.","journal-title":"Neoplasia"},{"issue":"20","key":"1851_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205127","volume":"13","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang T, Sun M, Ji X, Xie M, Huang W, Xia L. Therapeutic values of myeloid-derived suppressor cells in hepatocellular carcinoma: facts and hopes. Cancers (Basel). 2021;13(20): 5127.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"1851_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133375","volume":"13","author":"A Vogt","year":"2021","unstructured":"Vogt A, Sadeghlar F, Ayub TH, Schneider C, M\u00f6hring C, Zhou T, Mahn R, Bartels A, Praktiknjo M, Kornek MT. Alpha-fetoprotein-and CD40ligand-expressing dendritic cells for immunotherapy of hepatocellular carcinoma. Cancers (Basel). 2021;13(13): 3375.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1851_CR95","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/hep.32419","volume":"76","author":"S Suthen","year":"2022","unstructured":"Suthen S, Lim CJ, Nguyen PH, Dutertre CA, Lai HL, Wasser M, Chua C, Lim TK, Leow WQ, Loh TJ. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. Hepatology. 2022;76(5):1329\u201344.","journal-title":"Hepatology"},{"key":"1851_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.775462","volume":"9","author":"X Hao","year":"2021","unstructured":"Hao X, Sun G, Zhang Y, Kong X, Rong D, Song J, Tang W, Wang X. Targeting immune cells in the tumor microenvironment of HCC: new opportunities and challenges. Front Cell Dev Biol. 2021;9: 775462.","journal-title":"Front Cell Dev Biol"},{"issue":"13","key":"1851_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133248","volume":"13","author":"E Gonzalez-Sanchez","year":"2021","unstructured":"Gonzalez-Sanchez E, Vaquero J, F\u00e9rnandez-Barrena MG, Lasarte JJ, Avila MA, Sarobe P, Reig M, Calvo M, Fabregat I. The TGF-\u03b2 pathway: a pharmacological target in hepatocellular carcinoma? Cancers. 2021;13(13): 3248.","journal-title":"Cancers"},{"key":"1851_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133308","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023;14: 1133308.","journal-title":"Front Immunol"},{"issue":"11","key":"1851_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105631","volume":"9","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhao Q, Zhao B, Zheng Y, Zhuang Q, Liao N, Wang P, Cai Z, Zhang D, Zeng Y. Remodeling tumor-associated neutrophils to enhance dendritic cell-based HCC neoantigen nano-vaccine efficiency. Adv Sci. 2022;9(11): 2105631.","journal-title":"Adv Sci"},{"issue":"4","key":"1851_CR100","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41575-021-00568-5","volume":"19","author":"D Geh","year":"2022","unstructured":"Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022;19(4):257\u201373.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"24","key":"1851_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70551","volume":"13","author":"Y Lang","year":"2024","unstructured":"Lang Y, Fu W, Xu W, Ma C, Tian X, Hao C, Ding S. Prognostic value of N1\/N2 neutrophils heterogeneity and tertiary lymphoid structure in hepatocellular carcinoma patients. Cancer Med. 2024;13(24): e70551.","journal-title":"Cancer Med"},{"issue":"12","key":"1851_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122899","volume":"13","author":"K Arvanitakis","year":"2021","unstructured":"Arvanitakis K, Mitroulis I, Germanidis G. Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy. Cancers (Basel). 2021;13(12): 2899.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1851_CR103","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/cac2.12388","volume":"43","author":"X Zhan","year":"2023","unstructured":"Zhan X, Wu R, Kong XH, You Y, He K, Sun XY, Huang Y, Chen WX, Duan L. Elevated neutrophil extracellular traps by HBV-mediated S100A9-TLR4\/RAGE-ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma. Cancer Commun. 2023;43(2):225\u201345.","journal-title":"Cancer Commun"},{"issue":"1","key":"1851_CR104","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40164-024-00476-9","volume":"13","author":"X-T Shen","year":"2024","unstructured":"Shen X-T, Xie S-Z, Zheng X, Zou T-T, Hu B-Y, Xu J, Liu L, Xu Y-F, Wang X-F, Wang H. Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma. Exp Hematol Oncol. 2024;13(1):20.","journal-title":"Exp Hematol Oncol"},{"key":"1851_CR105","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S303588","author":"X Guan","year":"2021","unstructured":"Guan X, Lu Y, Zhu H, Yu S, Zhao W, Chi X, Xie C, Yin Z. The crosstalk between cancer cells and neutrophils enhances hepatocellular carcinoma metastasis via neutrophil extracellular traps-associated cathepsin G component: a potential therapeutic target. J Hepatocell Carcinoma. 2021. https:\/\/doi.org\/10.2147\/JHC.S303588.","journal-title":"J Hepatocell Carcinoma"},{"issue":"4","key":"1851_CR106","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/jleuko\/qiad004","volume":"113","author":"Y Sheng","year":"2023","unstructured":"Sheng Y, Peng W, Huang Y, Cheng L, Meng Y, Kwantwi LB, Yang J, Xu J, Xiao H, Kzhyshkowska J. Tumor-activated neutrophils promote metastasis in breast cancer via the G-CSF-RLN2-MMP-9 axis. J Leukoc Biol. 2023;113(4):383\u201399.","journal-title":"J Leukoc Biol"},{"issue":"7","key":"1851_CR107","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.7150\/thno.104557","volume":"15","author":"W Bi","year":"2025","unstructured":"Bi W, Li X, Jiang Y, Gao T, Zhao H, Han Q, Zhang J. Tumor-derived exosomes induce neutrophil infiltration and reprogramming to promote T-cell exhaustion in hepatocellular carcinoma. Theranostics. 2025;15(7):2852.","journal-title":"Theranostics"},{"issue":"4","key":"1851_CR108","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jcmgh.2023.01.006","volume":"15","author":"F Ying","year":"2023","unstructured":"Ying F, Chan MSM, Lee TKW. Cancer-associated fibroblasts in hepatocellular carcinoma and cholangiocarcinoma. Cell Mol Gastroenterol Hepatol. 2023;15(4):985\u201399.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"10","key":"1851_CR109","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41575-023-00821-z","volume":"20","author":"B Cogliati","year":"2023","unstructured":"Cogliati B, Yashaswini CN, Wang S, Sia D, Friedman SL. Friend or foe? The elusive role of hepatic stellate cells in liver cancer. Nat Rev Gastroenterol Hepatol. 2023;20(10):647\u201361.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1851_CR110","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40364-022-00406-z","volume":"10","author":"H Peng","year":"2022","unstructured":"Peng H, Zhu E, Zhang Y. Advances of cancer-associated fibroblasts in liver cancer. Biomark Res. 2022;10(1):59.","journal-title":"Biomark Res"},{"key":"1851_CR111","doi-asserted-by":"crossref","unstructured":"Cadamuro M, Nuozzi G, Simioni P, Fabris L. The tumor microenvironment in hepatocarcinoma: dissecting the functions of cancer-associated fibroblasts. Hepatoma Res 2023;9.","DOI":"10.20517\/2394-5079.2023.94"},{"issue":"3","key":"1851_CR112","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/cancers13030469","volume":"13","author":"JC L\u00f3pez-Gil","year":"2021","unstructured":"L\u00f3pez-Gil JC, Martin-Hijano L, Hermann PC, Sainz B Jr. The CXCL12 crossroads in cancer stem cells and their niche. Cancers (Basel). 2021;13(3):469.","journal-title":"Cancers (Basel)"},{"key":"1851_CR113","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.molimm.2022.09.010","volume":"151","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Hu Y, Wu Y, Qi Q, Wang J, Chen L, Wang F. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook. Mol Immunol. 2022;151:218\u201330.","journal-title":"Mol Immunol"},{"key":"1851_CR114","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2022.07.006","volume":"67","author":"X Xiang","year":"2022","unstructured":"Xiang X, Niu Y-R, Wang Z-H, Ye L-L, Peng W-B, Zhou Q. Cancer-associated fibroblasts: vital suppressors of the immune response in the tumor microenvironment. Cytokine Growth Factor Rev. 2022;67:35\u201348.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1851_CR115","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.ijbiomac.2022.09.129","volume":"221","author":"S Vimalraj","year":"2022","unstructured":"Vimalraj S. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. Int J Biol Macromol. 2022;221:1428\u201338.","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"1851_CR116","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/17474124.2021.1842732","volume":"15","author":"H Li","year":"2021","unstructured":"Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol. 2021;15(3):217\u201333.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"7931","key":"1851_CR117","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","volume":"610","author":"A Filliol","year":"2022","unstructured":"Filliol A, Saito Y, Nair A, Dapito DH, Yu L-X, Ravichandra A, Bhattacharjee S, Affo S, Fujiwara N, Su H. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature. 2022;610(7931):356\u201365.","journal-title":"Nature"},{"issue":"18","key":"1851_CR118","doi-asserted-by":"publisher","first-page":"10777","DOI":"10.3390\/ijms231810777","volume":"23","author":"P-W Wang","year":"2022","unstructured":"Wang P-W, Lin T-Y, Yang P-M, Yeh C-T, Pan T-L. Hepatic stellate cell modulates the immune microenvironment in the progression of hepatocellular carcinoma. Int J Mol Sci. 2022;23(18):10777.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"1851_CR119","doi-asserted-by":"publisher","first-page":"15292","DOI":"10.3390\/ijms232315292","volume":"23","author":"E Ali","year":"2022","unstructured":"Ali E, Trailin A, Ambrozkiewicz F, Li\u0161ka V, Hemminki K. Activated hepatic stellate cells in hepatocellular carcinoma: their role as a potential target for future therapies. Int J Mol Sci. 2022;23(23):15292.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1851_CR120","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/ph18040507","volume":"18","author":"H Xiong","year":"2025","unstructured":"Xiong H, Guo J. Targeting hepatic stellate cells for the prevention and treatment of liver cirrhosis and hepatocellular carcinoma: strategies and clinical translation. Pharmaceuticals. 2025;18(4):507.","journal-title":"Pharmaceuticals"},{"issue":"6","key":"1851_CR121","doi-asserted-by":"publisher","first-page":"G741","DOI":"10.1152\/ajpgi.00134.2024","volume":"327","author":"H Urushima","year":"2024","unstructured":"Urushima H, Matsubara T, Qiongya G, Daikoku A, Takayama M, Kadono C, Nakai H, Ikeya Y, Yuasa H, Ikeda K. AHCC inhibited hepatic stellate cells activation by regulation of cytoglobin induction via TLR2-SAPK\/JNK pathway and collagen production via TLR4-NF-\u03ba\u03b2 pathway. Am J Physiol Gastrointestinal Liver Physiol. 2024;327(6):G741\u201353.","journal-title":"Am J Physiol Gastrointestinal Liver Physiol"},{"issue":"1","key":"1851_CR122","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s42003-024-06245-y","volume":"7","author":"Y Mao","year":"2024","unstructured":"Mao Y, Wu C, Wang X, Zhang F, Qi X, Li X, Li P, Tang B. Fluorescence imaging sheds light on the immune evasion mechanisms of hepatic stellate cells mediated by superoxide anion. Commun Biol. 2024;7(1):558.","journal-title":"Commun Biol"},{"issue":"1","key":"1851_CR123","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymthe.2022.09.012","volume":"31","author":"X Liu","year":"2023","unstructured":"Liu X, Zhou J, Wu H, Chen S, Zhang L, Tang W, Duan L, Wang Y, McCabe E, Hu M. Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma. Mol Ther. 2023;31(1):119\u201333.","journal-title":"Mol Ther"},{"key":"1851_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.694145","volume":"11","author":"S Bao","year":"2021","unstructured":"Bao S, Jiang X, Jin S, Tu P, Lu J. TGF-\u03b21 induces immune escape by enhancing PD-1 and CTLA-4 expression on T lymphocytes in hepatocellular carcinoma. Front Oncol. 2021;11: 694145.","journal-title":"Front Oncol"},{"issue":"3","key":"1851_CR125","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.hbpd.2021.04.007","volume":"20","author":"H Li","year":"2021","unstructured":"Li H, Ding P, Peng B, Ming Y-Z. Cross-talk between hepatic stellate cells and T lymphocytes in liver fibrosis. Hepatobiliary Pancreat Dis Int. 2021;20(3):207\u201314.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"6","key":"1851_CR126","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-020-00411-3","volume":"18","author":"J Gracia-Sancho","year":"2021","unstructured":"Gracia-Sancho J, Caparr\u00f3s E, Fern\u00e1ndez-Iglesias A, Franc\u00e9s R. Role of liver sinusoidal endothelial cells in liver diseases. Nat Rev Gastroenterol Hepatol. 2021;18(6):411\u201331.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1851_CR127","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1007\/s11033-021-06269-1","volume":"48","author":"H Ma","year":"2021","unstructured":"Ma H, Liu X, Zhang M, Niu J. Liver sinusoidal endothelial cells are implicated in multiple fibrotic mechanisms. Mol Biol Rep. 2021;48:2803\u201315.","journal-title":"Mol Biol Rep"},{"issue":"3","key":"1851_CR128","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3350\/cmh.2024.0022","volume":"30","author":"J Qu","year":"2024","unstructured":"Qu J, Wang L, Li Y, Li X. Liver sinusoidal endothelial cell: an important yet often overlooked player in the liver fibrosis. Clin Mol Hepatol. 2024;30(3):303.","journal-title":"Clin Mol Hepatol"},{"key":"1851_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.matdes.2024.113242","author":"S Chen","year":"2024","unstructured":"Chen S, Jin L, Zeng Z, Chen G. Nanoparticle-based delivery system for normalization of liver sinusoidal endothelial cells in hepatocellular carcinoma. Mater Des. 2024. https:\/\/doi.org\/10.1016\/j.matdes.2024.113242.","journal-title":"Mater Des"},{"issue":"11","key":"1851_CR130","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00018-023-04966-7","volume":"80","author":"R-I Velliou","year":"2023","unstructured":"Velliou R-I, Legaki A-I, Nikolakopoulou P, Vlachogiannis NI, Chatzigeorgiou A. Liver endothelial cells in NAFLD and transition to NASH and HCC. Cell Mol Life Sci. 2023;80(11):314.","journal-title":"Cell Mol Life Sci"},{"issue":"19","key":"1851_CR131","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.3390\/cancers13194876","volume":"13","author":"N Rico Montanari","year":"2021","unstructured":"Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The role of cytokines in the different stages of hepatocellular carcinoma. Cancers (Basel). 2021;13(19):4876.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1851_CR132","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1053\/j.gastro.2023.02.005","volume":"164","author":"C Zhou","year":"2023","unstructured":"Zhou C, Weng J, Liu C, Liu S, Hu Z, Xie X, Gao D, Zhou Q, Sun J, Xu R. Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti\u2013PD-1 therapy efficacy in hepatocellular carcinoma. Gastroenterology. 2023;164(7):1261\u201378.","journal-title":"Gastroenterology"},{"issue":"5","key":"1851_CR133","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41419-022-04935-1","volume":"13","author":"H Xu","year":"2022","unstructured":"Xu H, Zhao J, Li J, Zhu Z, Cui Z, Liu R, Lu R, Yao Z, Xu Q. Cancer associated fibroblast\u2013derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1\u03b1\/ZEB1 axis. Cell Death Dis. 2022;13(5):478.","journal-title":"Cell Death Dis"},{"key":"1851_CR134","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S450959","author":"Z Wu","year":"2024","unstructured":"Wu Z, Sun L, Xu Y, Huang H, Wu Z, Qiu B, Yan J, Yin X. The value of chemokine and chemokine receptors in diagnosis, prognosis, and immunotherapy of hepatocellular carcinoma. Cancer Manag Res. 2024. https:\/\/doi.org\/10.2147\/CMAR.S450959.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1851_CR135","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/imm.13611","volume":"169","author":"W Yu","year":"2023","unstructured":"Yu W, He J, Wang F, He Q, Shi Y, Tao X, Sun B. NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-\u03b3\/p-STAT1\/IRF1 pathway. Immunology. 2023;169(1):69\u201382.","journal-title":"Immunology"},{"key":"1851_CR136","volume":"30","author":"Y Numata","year":"2022","unstructured":"Numata Y, Akutsu N, Ishigami K, Koide H, Wagatsuma K, Motoya M, Sasaki S, Nakase H. Synergistic effect of IFN-\u03b3 and IL-1\u03b2 on PD-L1 expression in hepatocellular carcinoma. Biochem Biophys Rep. 2022;30: 101270.","journal-title":"Biochem Biophys Rep"},{"issue":"2","key":"1851_CR137","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/cancers13020167","volume":"13","author":"B Mirlekar","year":"2021","unstructured":"Mirlekar B, Pylayeva-Gupta Y. IL-12 family cytokines in cancer and immunotherapy. Cancers (Basel). 2021;13(2):167.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"1851_CR138","doi-asserted-by":"publisher","first-page":"8112","DOI":"10.3390\/ijms23158112","volume":"23","author":"EF Brandt","year":"2022","unstructured":"Brandt EF, Baues M, Wirtz TH, May J-N, Fischer P, Beckers A, Sch\u00fcre B-C, Sahin H, Trautwein C, Lammers T. Chemokine CXCL10 modulates the tumor microenvironment of fibrosis-associated hepatocellular carcinoma. Int J Mol Sci. 2022;23(15):8112.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1851_CR139","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s13273-021-00215-9","volume":"18","author":"YJ Cho","year":"2022","unstructured":"Cho YJ, Lee HH, Kang H, Cho H. The antitumor effect of natural killer cells against hepatocellular carcinoma through CXCL9. Mol Cell Toxicol. 2022;18(3):409\u201317.","journal-title":"Mol Cell Toxicol"},{"key":"1851_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101170","author":"AM Roy","year":"2023","unstructured":"Roy AM, Iyer R, Chakraborty S. The extracellular matrix in hepatocellular carcinoma: mechanisms and therapeutic vulnerability. Cell Rep Med. 2023. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101170.","journal-title":"Cell Rep Med"},{"issue":"21","key":"1851_CR141","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.3390\/cancers13215586","volume":"13","author":"T S\u00fckei","year":"2021","unstructured":"S\u00fckei T, Palma E, Urbani L. Interplay between cellular and non-cellular components of the tumour microenvironment in hepatocellular carcinoma. Cancers (Basel). 2021;13(21):5586.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1851_CR142","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.jhep.2022.08.028","volume":"77","author":"EK Mitten","year":"2022","unstructured":"Mitten EK, Baffy G. Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2022;77(6):1642\u201356.","journal-title":"J Hepatol"},{"issue":"3","key":"1851_CR143","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/acs.analchem.3c03771","volume":"96","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Ye Z, Liu Y, Zhang J, Kuermanbayi S, Zhou Y, Guo H, Xu F, Li F. Investigating the role of extracellular matrix stiffness in modulating the ferroptosis process in hepatocellular carcinoma cells via scanning electrochemical microscopy. Anal Chem. 2024;96(3):1102\u201311.","journal-title":"Anal Chem"},{"issue":"12","key":"1851_CR144","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.3390\/cancers13123076","volume":"13","author":"Y-T Lee","year":"2021","unstructured":"Lee Y-T, Tran BV, Wang JJ, Liang IY, You S, Zhu Y, Agopian VG, Tseng H-R, Yang JD. The role of extracellular vesicles in disease progression and detection of hepatocellular carcinoma. Cancers. 2021;13(12):3076.","journal-title":"Cancers"},{"key":"1851_CR145","doi-asserted-by":"publisher","first-page":"1368898","DOI":"10.3389\/fimmu.2024.1368898","volume":"15","author":"L Tian","year":"2024","unstructured":"Tian L, Lu J, Ng IO-L. Extracellular vesicles and cancer stemness in hepatocellular carcinoma\u2013is there a link? Front Immunol. 2024;15:1368898.","journal-title":"Front Immunol"},{"issue":"4","key":"1851_CR146","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/gutjnl-2020-322526","volume":"70","author":"X Wang","year":"2021","unstructured":"Wang X, He Y, Mackowiak B, Gao B. Micrornas as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2021;70(4):784\u201395.","journal-title":"Gut"},{"issue":"10","key":"1851_CR147","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/s42255-022-00642-5","volume":"4","author":"Q-T Chen","year":"2022","unstructured":"Chen Q-T, Zhang Z-Y, Huang Q-L, Chen H-Z, Hong W-B, Lin T, Zhao W-X, Wang X-M, Ju C-Y, Wu L-Z. HK1 from hepatic stellate cell\u2013derived extracellular vesicles promotes progression of hepatocellular carcinoma. Nat Metab. 2022;4(10):1306\u201321.","journal-title":"Nat Metab"},{"key":"1851_CR148","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.omtn.2021.12.017","volume":"27","author":"J Tan","year":"2022","unstructured":"Tan J, Zhang J, Wang M, Wang Y, Dong M, Ma X, Sun B, Liu S, Zhao Z, Chen L. DRAM1 increases the secretion of PKM2-enriched EVs from hepatocytes to promote macrophage activation and disease progression in ALD. Molecular Therapy-Nucleic Acids. 2022;27:375\u201389.","journal-title":"Molecular Therapy-Nucleic Acids"},{"issue":"1","key":"1851_CR149","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-020-00453-8","volume":"6","author":"Q Li","year":"2021","unstructured":"Li Q, Ni Y, Zhang L, Jiang R, Xu J, Yang H, Hu Y, Qiu J, Pu L, Tang J. HIF-1\u03b1-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal Transduct Target Ther. 2021;6(1):76.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1851_CR150","doi-asserted-by":"publisher","first-page":"109","DOI":"10.21037\/atm-21-4222","volume":"10","author":"Q Chu","year":"2022","unstructured":"Chu Q, Gu X, Zheng Q, Zhu H. Regulatory mechanism of HIF-1\u03b1 and its role in liver diseases: a narrative review. Ann Transl Med. 2022;10(2):109.","journal-title":"Ann Transl Med"},{"issue":"5","key":"1851_CR151","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1002\/jcp.30128","volume":"236","author":"N Yang","year":"2021","unstructured":"Yang N, Wang T, Li Q, Han F, Wang Z, Zhu R, Zhou J. HBxIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1\u03b1. J Cell Physiol. 2021;236(5):3863\u201380.","journal-title":"J Cell Physiol"},{"issue":"1","key":"1851_CR152","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12920-024-01867-x","volume":"17","author":"X Qin","year":"2024","unstructured":"Qin X, Sun H, Hu S, Pan Y, Wang S. A hypoxia\u2013glycolysis\u2013lactate-related gene signature for prognosis prediction in hepatocellular carcinoma. BMC Med Genomics. 2024;17(1):88.","journal-title":"BMC Med Genomics"},{"issue":"1","key":"1851_CR153","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3892\/ijmm.2024.5383","volume":"54","author":"S Yao","year":"2024","unstructured":"Yao S, Chai H, Tao T, Zhang L, Yang X, Li X, Yi Z, Wang Y, An J, Wen G. Role of lactate and lactate metabolism in liver diseases. Int J Mol Med. 2024;54(1):59.","journal-title":"Int J Mol Med"},{"issue":"7","key":"1851_CR154","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/cells10071715","volume":"10","author":"MH-R Bao","year":"2021","unstructured":"Bao MH-R, Wong CC-L. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells. 2021;10(7):1715.","journal-title":"Cells"},{"issue":"3","key":"1851_CR155","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/ijms26030968","volume":"26","author":"Q Tan","year":"2025","unstructured":"Tan Q, Deng S, Xiong L. Role of kynurenine and its derivatives in liver diseases: recent advances and future clinical perspectives. Int J Mol Sci. 2025;26(3):968.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"1851_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205180","volume":"13","author":"S Krishnamurthy","year":"2021","unstructured":"Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin J-S, Guillemin GJ, Heng B. Involvement of kynurenine pathway in hepatocellular carcinoma. Cancers (Basel). 2021;13(20): 5180.","journal-title":"Cancers (Basel)"},{"key":"1851_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.690600","volume":"12","author":"N Han","year":"2021","unstructured":"Han N, Pan Z, Liu G, Yang R, Yujing B. Hypoxia: the \u201cinvisible pusher\u201d of gut microbiota. Front Microbiol. 2021;12: 690600.","journal-title":"Front Microbiol"},{"issue":"1","key":"1851_CR158","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41420-025-02413-z","volume":"11","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li Y, Lin Y, Cao C, Chen D, Huang X, Li C, Xu H, Lai H, Chen H. Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota. Cell Death Discov. 2025;11(1):140.","journal-title":"Cell Death Discov"},{"key":"1851_CR159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658681","volume":"12","author":"L Hu","year":"2021","unstructured":"Hu L, Liu Y, Kong X, Wu R, Peng Q, Zhang Y, Zhou L, Duan L. Fusobacterium nucleatum facilitates M2 macrophage polarization and colorectal carcinoma progression by activating TLR4\/NF-\u03ba b\/S100A9 cascade. Front Immunol. 2021;12: 658681.","journal-title":"Front Immunol"},{"issue":"12","key":"1851_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29122727","volume":"29","author":"Y Luo","year":"2024","unstructured":"Luo Y, Zhang G, Hu C, Huang L, Wang D, Chen Z, Wang Y. The role of natural products from herbal medicine in TLR4 signaling for colorectal cancer treatment. Molecules. 2024;29(12): 2727.","journal-title":"Molecules"},{"issue":"2","key":"1851_CR161","doi-asserted-by":"publisher","first-page":"e01127","DOI":"10.1128\/msystems.01127-22","volume":"8","author":"Y Kang","year":"2023","unstructured":"Kang Y, Kuang X, Yan H, Ren P, Yang X, Liu H, Liu Q, Yang H, Kang X, Shen X. A novel synbiotic alleviates autoimmune hepatitis by modulating the gut microbiota-liver axis and inhibiting the hepatic TLR4\/NF-\u03baB\/NLRP3 signaling pathway. Msystems. 2023;8(2):e01127-e1122.","journal-title":"Msystems"},{"issue":"Suppl","key":"1851_CR162","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.3350\/cmh.2024.0837","volume":"31","author":"S Zhang","year":"2024","unstructured":"Zhang S, Mak L-Y, Yuen M-F, Seto W-K. Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B. Clin Mol Hepatol. 2024;31(Suppl):S182.","journal-title":"Clin Mol Hepatol"},{"key":"1851_CR163","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363996","volume":"15","author":"S Soleiman-Meigooni","year":"2024","unstructured":"Soleiman-Meigooni S, Yarahmadi A, Kheirkhah A-H, Afkhami H. Recent advances in different interactions between toll-like receptors and hepatitis B infection: a review. Front Immunol. 2024;15: 1363996.","journal-title":"Front Immunol"},{"issue":"1","key":"1851_CR164","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1869388","volume":"10","author":"X Zao","year":"2021","unstructured":"Zao X, Cheng J, Shen C, Guan G, Feng X, Zou J, Zhang J, Liu T, Zheng H, Zhang T. NFATc3 inhibits hepatocarcinogenesis and HBV replication via positively regulating RIG-I-mediated interferon transcription. Oncoimmunology. 2021;10(1): 1869388.","journal-title":"Oncoimmunology"},{"issue":"10","key":"1851_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/v14102275","volume":"14","author":"G Yang","year":"2022","unstructured":"Yang G, Wan P, Zhang Y, Tan Q, Qudus MS, Yue Z, Luo W, Zhang W, Ouyang J, Li Y. Innate immunity, inflammation, and intervention in HBV infection. Viruses. 2022;14(10): 2275.","journal-title":"Viruses"},{"key":"1851_CR166","doi-asserted-by":"publisher","first-page":"1322892","DOI":"10.3389\/fmicb.2023.1322892","volume":"14","author":"F Wang","year":"2023","unstructured":"Wang F, Song H, Xu F, Xu J, Wang L, Yang F, Zhu Y, Tan G. Role of hepatitis B virus non-structural protein HBx on HBV replication, interferon signaling, and hepatocarcinogenesis. Front Microbiol. 2023;14:1322892.","journal-title":"Front Microbiol"},{"issue":"4","key":"1851_CR167","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/v15040857","volume":"15","author":"K Padarath","year":"2023","unstructured":"Padarath K, Deroubaix A, Kramvis A. The complex role of HBeAg and its precursors in the pathway to hepatocellular carcinoma. Viruses. 2023;15(4):857.","journal-title":"Viruses"},{"key":"1851_CR168","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.829923","volume":"13","author":"H You","year":"2022","unstructured":"You H, Qin S, Zhang F, Hu W, Li X, Liu D, Kong F, Pan X, Zheng K, Tang R. Regulation of pattern-recognition receptor signaling by HBX during hepatitis B virus infection. Front Immunol. 2022;13: 829923.","journal-title":"Front Immunol"},{"issue":"1","key":"1851_CR169","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","volume":"22","author":"M Iannacone","year":"2022","unstructured":"Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol. 2022;22(1):19\u201332.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1851_CR170","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12865-022-00488-2","volume":"23","author":"D Jiang","year":"2022","unstructured":"Jiang D, Chen C, Yan D, Zhang X, Liu X, Yan D, Cui D, Yang S. Exhausted phenotype of circulating CD8+ T cell subsets in hepatitis B virus carriers. BMC Immunol. 2022;23(1):18.","journal-title":"BMC Immunol"},{"issue":"5","key":"1851_CR171","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/v16050707","volume":"16","author":"M Broholm","year":"2024","unstructured":"Broholm M, Mathiasen A-S, Apol \u00c1D, Weis N. The adaptive immune response in hepatitis B virus-associated hepatocellular carcinoma is characterized by dysfunctional and exhausted HBV-specific T cells. Viruses. 2024;16(5):707.","journal-title":"Viruses"},{"issue":"1","key":"1851_CR172","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12885-023-11804-3","volume":"24","author":"J Li","year":"2024","unstructured":"Li J, Chen H, Bai L, Tang H. Identification of CD8+ T-cell exhaustion signatures for prognosis in HBV-related hepatocellular carcinoma patients by integrated analysis of single-cell and bulk RNA-sequencing. BMC Cancer. 2024;24(1):53.","journal-title":"BMC Cancer"},{"issue":"8","key":"1851_CR173","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3390\/cells10081909","volume":"10","author":"L Montella","year":"2021","unstructured":"Montella L, Sarno F, Ambrosino A, Facchini S, D\u2019Ant\u00f2 M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L. The role of immunotherapy in a tolerogenic environment: current and future perspectives for hepatocellular carcinoma. Cells. 2021;10(8):1909.","journal-title":"Cells"},{"key":"1851_CR174","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.805625","volume":"8","author":"S Zhong","year":"2021","unstructured":"Zhong S, Zhang T, Tang L, Li Y. Cytokines and chemokines in HBV infection. Front Mol Biosci. 2021;8: 805625.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"1851_CR175","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/vaccines11030614","volume":"11","author":"J Zhang","year":"2023","unstructured":"Zhang J, Hu C, Xie X, Qi L, Li C, Li S. Immune checkpoint inhibitors in HBV-caused hepatocellular carcinoma therapy. Vaccines. 2023;11(3):614.","journal-title":"Vaccines"},{"issue":"4","key":"1851_CR176","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.dld.2020.08.041","volume":"53","author":"B Godbert","year":"2021","unstructured":"Godbert B, Petitpain N, Lopez A, Nisse Y-E, Gillet P. Hepatitis B reactivation and immune check point inhibitors. Dig Liver Dis. 2021;53(4):452\u20135.","journal-title":"Dig Liver Dis"},{"key":"1851_CR177","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","volume":"15","author":"F Meng","year":"2021","unstructured":"Meng F, Zhao J, Tan AT, Hu W, Wang S-Y, Jin J, Wu J, Li Y, Shi L, Fu J-L. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. Hepatol Int. 2021;15:1402\u201312.","journal-title":"Hepatol Int"},{"key":"1851_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2024.110199","volume":"599","author":"A Kar","year":"2024","unstructured":"Kar A, Mukherjee S, Mukherjee S, Biswas A. Ubiquitin: a double-edged sword in hepatitis B virus-induced hepatocellular carcinoma. Virology. 2024;599: 110199.","journal-title":"Virology"},{"issue":"3","key":"1851_CR179","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/hep.31839","volume":"74","author":"HN Kim","year":"2021","unstructured":"Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ. Risk of HCC with hepatitis B viremia among HIV\/HBV-coinfected persons in North America. Hepatology. 2021;74(3):1190\u2013202.","journal-title":"Hepatology"},{"key":"1851_CR180","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.713981","volume":"8","author":"Z Cheng","year":"2021","unstructured":"Cheng Z, Lin P, Cheng N. HBV\/HIV coinfection: impact on the development and clinical treatment of liver diseases. Front Med. 2021;8: 713981.","journal-title":"Front Med"},{"issue":"12","key":"1851_CR181","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.4254\/wjh.v16.i12.1480","volume":"16","author":"J-L Yang","year":"2024","unstructured":"Yang J-L, Yang J, Fang R-F, Sai W-L, Yao D-F, Yao M. Hypoxia upregulates hepatic angiopoietin-2 transcription to promote the progression of hepatocellular carcinoma. World J Hepatol. 2024;16(12):1480.","journal-title":"World J Hepatol"},{"key":"1851_CR182","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cca.2022.11.012","volume":"538","author":"Z Liu","year":"2023","unstructured":"Liu Z, Li Y, Wang Y, Bai X, Zhang Y. Exosomes in HBV infection. Clin Chim Acta. 2023;538:65\u20139.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"1851_CR183","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12951-024-02544-y","volume":"22","author":"X Wu","year":"2024","unstructured":"Wu X, Niu J, Shi Y. Exosomes target HBV-host interactions to remodel the hepatic immune microenvironment. J Nanobiotechnology. 2024;22(1):315.","journal-title":"J Nanobiotechnology"},{"key":"1851_CR184","doi-asserted-by":"publisher","first-page":"1042368","DOI":"10.3389\/fimmu.2022.1042368","volume":"13","author":"N Friedlov\u00e1","year":"2022","unstructured":"Friedlov\u00e1 N, Zavadil Kok\u00e1\u0161 F, Hupp TR, Vojt\u011b\u0161ek B, Nekulov\u00e1 M. IFITM protein regulation and functions: far beyond the fight against viruses. Front Immunol. 2022;13:1042368.","journal-title":"Front Immunol"},{"key":"1851_CR185","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-024-02214-z","author":"J Zhang","year":"2024","unstructured":"Zhang J, Liu J, Ni J, Lin X, Fan L, Sun G. Exosomes derived from endoplasmic reticulum stressed hepatocellular carcinoma cells enhance the antitumor immunity of dendritic cells. Inflammation. 2024. https:\/\/doi.org\/10.1007\/s10753-024-02214-z.","journal-title":"Inflammation"},{"issue":"3","key":"1851_CR186","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70287","volume":"97","author":"X Miao","year":"2025","unstructured":"Miao X, Zhou X, Liu C, Shi H, Liu F, Ma Y, Shi H. Alcohol-induced dendritic cells and their exosomes promote T-cell immunity in hepatitis B virus transgenic mice and patients with chronic hepatitis B. J Med Virol. 2025;97(3): e70287.","journal-title":"J Med Virol"},{"key":"1851_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e39176","author":"S Zheng","year":"2024","unstructured":"Zheng S, Qi W, Xue T, Zao X, Xie J, Zhang P, Li X, Ye Y, Liu A. Chinese medicine in the treatment of chronic hepatitis B: the mechanisms of signal pathway regulation. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e39176.","journal-title":"Heliyon"},{"key":"1851_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101546","author":"J-H Hung","year":"2024","unstructured":"Hung J-H, Teng C-F, Hung H-C, Chen Y-L, Chen P-J, Ho C-L, Chuang C-H, Huang W. Genomic instabilities in hepatocellular carcinoma: biomarkers and application in immunotherapies. Ann Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.aohep.2024.101546.","journal-title":"Ann Hepatol"},{"issue":"10","key":"1851_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101128","volume":"6","author":"M Ringelhan","year":"2024","unstructured":"Ringelhan M, Schuehle S, van de Klundert M, Kotsiliti E, Plissonnier M-L, Faure-Dupuy S, Riedl T, Lange S, Wisskirchen K, Thiele F. HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx. Jhep Reports. 2024;6(10): 101128.","journal-title":"Jhep Reports"},{"issue":"12","key":"1851_CR190","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.3390\/ijms25126606","volume":"25","author":"Y Jeong","year":"2024","unstructured":"Jeong Y, Han J, Jang KL. Reactive oxygen species induction by hepatitis B virus: implications for viral replication in p53-positive human hepatoma cells. Int J Mol Sci. 2024;25(12):6606.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"1851_CR191","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.3390\/cancers14194900","volume":"14","author":"BJ Beudeker","year":"2022","unstructured":"Beudeker BJ, Groothuismink ZM, van der Eijk AA, Debes JD, Boonstra A. Circulating cytokines reflect the etiology-specific immune environment in cirrhosis and HCC. Cancers. 2022;14(19):4900.","journal-title":"Cancers"},{"key":"1851_CR192","doi-asserted-by":"crossref","unstructured":"Abakar MAA, Ali AAH, Elhassan EDA, Altaher EAH, Musa NHA, Kafi SK, Osman AEF, Waggiallah H. A. Association of TNF-\u03b1, IFN-\u03b3, IL-6, and IL-10 with different clinical manifestations of hepatitis B infection. Ital  J Med 2023;17 (2).","DOI":"10.4081\/itjm.2023.1627"},{"key":"1851_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114472","volume":"161","author":"L Shan","year":"2023","unstructured":"Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X. Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis. Biomed Pharmacother. 2023;161: 114472.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1851_CR194","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/22221751.2022.2037393","volume":"11","author":"F Li","year":"2022","unstructured":"Li F, Deng Y, Zhang S, Zhu B, Wang J, Wang J, Wang X, Zhao Z, Deng W, Mao R. Human hepatocyte-enriched miRNA-192-3p promotes HBV replication through inhibiting Akt\/mTOR signalling by targeting ZNF143 in hepatic cell lines. Emerg Microbes Infect. 2022;11(1):616\u201328.","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"1851_CR195","doi-asserted-by":"publisher","DOI":"10.3390\/cells14040266","volume":"14","author":"A Sharip","year":"2025","unstructured":"Sharip A, Kunz J. Mechanosignaling via integrins: pivotal players in liver fibrosis progression and therapy. Cells. 2025;14(4): 266.","journal-title":"Cells"},{"issue":"1","key":"1851_CR196","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","volume":"7","author":"M Pinter","year":"2021","unstructured":"Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 2021;7(1):113\u201323.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1851_CR197","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/gutjnl-2022-327059","volume":"72","author":"C-Y Meng","year":"2023","unstructured":"Meng C-Y, Sun S, Liang Y, Xu H, Zhang C, Zhang M, Wang F-S, Fu Y-X, Peng H. Engineered anti-PDL1 with IFN\u03b1 targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut. 2023;72(8):1544\u201354.","journal-title":"Gut"},{"key":"1851_CR198","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1070961","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Han J, Yang Y, Chen Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13: 1070961.","journal-title":"Front Immunol"},{"issue":"10","key":"1851_CR199","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s11864-024-01246-9","volume":"25","author":"H Dong","year":"2024","unstructured":"Dong H, Zhang Z, Ni M, Xu X, Luo Y, Wang Y, Zhang H, Chen J. The trend of the treatment of advanced hepatocellular carcinoma: combination of immunotherapy and targeted therapy. Curr Treat Options Oncol. 2024;25(10):1239\u201356.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"1851_CR200","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001945","volume":"9","author":"JSL Wong","year":"2021","unstructured":"Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J, Ma KW, She WH, Tsang J, Lo CM. Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer. 2021;9(2): e001945.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1851_CR201","first-page":"942","volume":"14","author":"Y-Y Wei","year":"2022","unstructured":"Wei Y-Y, Fan J, Shan M-X, Yin D-D, Wang L-L, Ye W, Zhao W. TIGIT marks exhausted T cells and serves as a target for immune restoration in patients with chronic HBV infection. Am J Transl Res. 2022;14(2):942.","journal-title":"Am J Transl Res"},{"issue":"3","key":"1851_CR202","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","volume":"75","author":"M Kudo","year":"2021","unstructured":"Kudo M, Matilla A, Santoro A, Melero I, Graci\u00e1n AC, Acosta-Rivera M, Choo S-P, El-Khoueiry AB, Kuromatsu R, El-Rayes B. Checkmate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021;75(3):600\u20139.","journal-title":"J Hepatol"},{"key":"1851_CR203","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.02.009","volume":"167","author":"M Kudo","year":"2022","unstructured":"Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, Verslype C, Zagonel V, Fartoux L, Vogel A. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer. 2022;167:1\u201312.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1851_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47420-3","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z, Liu J, Zhang B, Yue J, Shi X, Cui K, Liu Z, Chang Z, Sun Z, Li M. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nat Commun. 2024;15(1): 3260.","journal-title":"Nat Commun"},{"issue":"17","key":"1851_CR205","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2217\/fon-2020-1290","volume":"17","author":"X Liu","year":"2021","unstructured":"Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncol. 2021;17(17):2243\u201356.","journal-title":"Future Oncol"},{"key":"1851_CR206","doi-asserted-by":"publisher","first-page":"1073133","DOI":"10.3389\/fimmu.2023.1073133","volume":"14","author":"H Zeng","year":"2023","unstructured":"Zeng H, Xu Q, Wang J, Xu X, Luo J, Zhang L, Luo C, Ying J, Li J. The effect of anti-PD-1\/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma. Front Immunol. 2023;14:1073133.","journal-title":"Front Immunol"},{"issue":"9","key":"1851_CR207","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1200\/JCO.22.00972","volume":"41","author":"T Yau","year":"2023","unstructured":"Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B. Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the CheckMate 040 trial. J Clin Oncol. 2023;41(9):1747\u201357.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1851_CR208","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo B-Y, Ren Z. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1851_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101270","volume":"7","author":"Z Chen","year":"2025","unstructured":"Chen Z, Xie T, Chen S, Li Z, Yao S, Lu X, He W, Tang C, Yang D, Li S. AI-based tumor-infiltrating lymphocyte scoring system for assessing HCC prognosis in patients undergoing liver resection. JHEP Rep. 2025;7(2): 101270.","journal-title":"JHEP Rep"},{"issue":"1","key":"1851_CR210","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1038\/s41467-021-24010-1","volume":"12","author":"DW-H Ho","year":"2021","unstructured":"Ho DW-H, Tsui Y-M, Chan L-K, Sze KM-F, Zhang X, Cheu JW-S, Chiu Y-T, Lee JM-F, Chan AC-Y, Cheung ET-Y. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun. 2021;12(1):3684.","journal-title":"Nat Commun"},{"key":"1851_CR211","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1079495","volume":"14","author":"R Sun","year":"2023","unstructured":"Sun R, Li J, Lin X, Yang Y, Liu B, Lan T, Xiao S, Deng A, Yin Z, Xu Y. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma. Front Immunol. 2023;14: 1079495.","journal-title":"Front Immunol"},{"issue":"4","key":"1851_CR212","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/imm.13738","volume":"171","author":"J He","year":"2024","unstructured":"He J, Miao R, Chen Y, Wang H, Liu M. The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma. Immunology. 2024;171(4):445\u201363.","journal-title":"Immunology"},{"issue":"4","key":"1851_CR213","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.800","volume":"12","author":"W He","year":"2022","unstructured":"He W, Hu Y, Chen D, Li Y, Ye D, Zhao Q, Lin L, Shi X, Lu L, Yin Z. Hepatocellular carcinoma-infiltrating \u03b3\u03b4 T cells are functionally defected and allogenic V\u03b42+ \u03b3\u03b4 T cell can be a promising complement. Clin Transl Med. 2022;12(4): e800.","journal-title":"Clin Transl Med"},{"issue":"4","key":"1851_CR214","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3350\/cmh.2024.0058","volume":"30","author":"X Wan","year":"2024","unstructured":"Wan X, Wisskirchen K, Jin T, Yang L, Wang X, Wu Xa, Liu F, Wu Y, Ma C, Pang Y. Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting. Clin Mol Hepatol. 2024;30(4):735.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"1851_CR215","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5501","volume":"62","author":"D Li","year":"2023","unstructured":"Li D, Qin J, Zhou T, Li Y, Cheng X, Chen Z, Chen J, Zheng W. Bispecific GPC3\/PD-1 CAR-T cells for the treatment of HCC. Int J Oncol. 2023;62(4): 53.","journal-title":"Int J Oncol"},{"key":"1851_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajg.2024.12.002","author":"M Li","year":"2025","unstructured":"Li M, Chen T, Huang R, Cen Y, Zhao F, Fan R, He G. Chimeric antigen receptor-T cells targeting AFP-GPC3 mediate increased antitumor efficacy in hepatocellular carcinoma. Arab J Gastroenterol. 2025. https:\/\/doi.org\/10.1016\/j.ajg.2024.12.002.","journal-title":"Arab J Gastroenterol"},{"issue":"9","key":"1851_CR217","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/cac2.12472","volume":"43","author":"Y Shi","year":"2023","unstructured":"Shi Y, Shi D, Chi J, Cui D, Tang X, Lin Y, Wang S, Li Z, Jin H, Zhai B. Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy. Cancer Commun. 2023;43(9):1064.","journal-title":"Cancer Commun"},{"issue":"5","key":"1851_CR218","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.ymthe.2021.01.021","volume":"29","author":"F Zou","year":"2021","unstructured":"Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, Li J. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. Mol Ther. 2021;29(5):1794\u2013807.","journal-title":"Mol Ther"},{"key":"1851_CR219","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.963031","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun H, Xing C, Jiang S, Yu K, Dai S, Kong H, Jin Y, Shan Y, Yang W, Wang Z. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-cells plus sorafenib, a case report. Front Immunol. 2022;13: 963031.","journal-title":"Front Immunol"},{"issue":"4","key":"1851_CR220","first-page":"566","volume":"73","author":"E Hildt","year":"2024","unstructured":"Hildt E, Hu J. New facet of CARs: HBV-specific CARs as inhibitors of virus morphogenesis and release. Gut. 2024;73(4):566\u20137.","journal-title":"Gut"},{"issue":"4","key":"1851_CR221","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040566","volume":"17","author":"DH Kim","year":"2025","unstructured":"Kim DH, Kim EM, Lee JS, Kim MN, Kim BK, Kim SU, Park JY, Choi GH, Ahn SH, Lee HW. Cytokine-induced killer cell immunotherapy reduces recurrence in patients with early-stage hepatocellular carcinoma. Cancers (Basel). 2025;17(4): 566.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1851_CR222","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/hep.32331","volume":"76","author":"S Pal","year":"2022","unstructured":"Pal S, Dey D, Chakraborty BC, Nandi M, Khatun M, Banerjee S, Santra A, Ghosh R, Ahammed SM, Chowdhury A. Diverse facets of MDSC in different phases of chronic HBV infection: impact on HBV-specific T-cell response and homing. Hepatology. 2022;76(3):759\u201374.","journal-title":"Hepatology"},{"issue":"8","key":"1851_CR223","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/jgh.16564","volume":"39","author":"M Gryziak","year":"2024","unstructured":"Gryziak M, Kraj L, Stec R. The role of tumor-associated macrophages in hepatocellular carcinoma\u2014from bench to bedside: a review. J Gastroenterol Hepatol. 2024;39(8):1489\u201399.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"1851_CR224","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052985","volume":"25","author":"J Arshad","year":"2024","unstructured":"Arshad J, Rao A, Repp ML, Rao R, Wu C, Merchant JL. Myeloid-derived suppressor cells: therapeutic target for gastrointestinal cancers. Int J Mol Sci. 2024;25(5): 2985.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1851_CR225","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02727-3","volume":"22","author":"A Aghamajidi","year":"2022","unstructured":"Aghamajidi A, Farhangnia P, Pashangzadeh S, Damavandi AR, Jafari R. Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy. Cancer Cell Int. 2022;22(1): 327.","journal-title":"Cancer Cell Int"},{"key":"1851_CR226","doi-asserted-by":"crossref","unstructured":"Zaheer S, Sureka N. Unlocking new frontiers: novel immune targets for next-gen cancer immunotherapy. Authorea Preprints, 2024. https:\/\/www.authorea.com\/doi\/full\/10.22541\/au.173170806.66836515","DOI":"10.22541\/au.173170806.66836515\/v1"},{"key":"1851_CR227","first-page":"95","volume":"17","author":"M Yazdanifar","year":"2016","unstructured":"Yazdanifar M, Zhou R, Mukherjee P. Emerging immunotherapeutics in adenocarcinomas: a focus on CAR-T cells. Curr Trends Immunol. 2016;17:95.","journal-title":"Curr Trends Immunol"},{"issue":"11","key":"1851_CR228","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou M-M, Matilla A. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564\u2013e204564.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1851_CR229","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1111\/cas.16247","volume":"115","author":"F Yan","year":"2024","unstructured":"Yan F, Zhu B, Shi K, Zhang Y, Zeng X, Zhang Q, Yang Z, Wang X. Prognostic and therapeutic potential of imbalance between PD-1+ CD8 and ICOS+ Treg cells in advanced HBV-HCC. Cancer Sci. 2024;115(8):2553\u201364.","journal-title":"Cancer Sci"},{"issue":"20","key":"1851_CR230","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204977","volume":"15","author":"A Agirre-Lizaso","year":"2023","unstructured":"Agirre-Lizaso A, Huici-Izagirre M, Urretabizkaia-Garmendia J, Rodrigues PM, Banales JM, Perugorria MJ. Targeting the heterogeneous tumour-associated macrophages in hepatocellular carcinoma. Cancers (Basel). 2023;15(20): 4977.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1851_CR231","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000056","volume":"10","author":"R Kelley","year":"2019","unstructured":"Kelley R, Gane E, Assenat E, Siebler J, Galle P, Merle P, Hourmand I, Cleverly A, Zhao Y, Gueorguieva I. A phase 2 study of galunisertib (TGF-\u03b21 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma. Clin Transl Gastroenterol. 2019;10(7): e00056.","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"1851_CR232","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s13402-024-01013-w","volume":"48","author":"N Yi","year":"2025","unstructured":"Yi N, Zhang L, Huang X, Ma J, Gao J. Lenvatinib-activated NDUFA4L2\/IL33\/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma. Cell Oncol. 2025;48(2):487\u2013504.","journal-title":"Cell Oncol"},{"issue":"8","key":"1851_CR233","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13636","volume":"57","author":"F Chen","year":"2024","unstructured":"Chen F, He Z, Wang C, Si J, Chen Z, Guo Y. Advances in the study of S100A9 in cardiovascular diseases. Cell Prolif. 2024;57(8): e13636.","journal-title":"Cell Prolif"},{"key":"1851_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217098","volume":"598","author":"Y Yu","year":"2024","unstructured":"Yu Y, Zhang C, Dong B, Zhang Z, Li X, Huang S, Tang D, Jing X, Yu S, Zheng T. Neutrophil extracellular traps promote immune escape in hepatocellular carcinoma by up-regulating CD73 through Notch2. Cancer Lett. 2024;598: 217098.","journal-title":"Cancer Lett"},{"issue":"11","key":"1851_CR235","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007353","volume":"11","author":"TM Bauer","year":"2023","unstructured":"Bauer TM, Santoro A, Lin C-C, Garrido-Laguna I, Joerger M, Greil R, Spreafico A, Yau T, Goebeler M-E, H\u00fctter-Kr\u00f6nke ML. Phase I\/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-\u03b2 monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. J Immunother Cancer. 2023;11(11): e007353.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1851_CR236","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"K-Y Shen","year":"2024","unstructured":"Shen K-Y, Zhu Y, Xie S-Z, Qin L-X. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024;17(1): 25.","journal-title":"J Hematol Oncol"},{"issue":"14","key":"1851_CR237","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411745","volume":"24","author":"J Radi\u0107","year":"2023","unstructured":"Radi\u0107 J, Ko\u017eik B, Nikoli\u0107 I, Kolarov-Bjelobrk I, Vasiljevi\u0107 T, Vranjkovi\u0107 B, Despotovi\u0107 S. Multiple roles of LOXL2 in the progression of hepatocellular carcinoma and its potential for therapeutic targeting. Int J Mol Sci. 2023;24(14): 11745.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1851_CR238","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10020312","volume":"10","author":"S Ferreira","year":"2021","unstructured":"Ferreira S, Saraiva N, Rijo P, Fernandes AS. LOXL2 inhibitors and breast cancer progression. Antioxidants. 2021;10(2): 312.","journal-title":"Antioxidants"},{"issue":"1","key":"1851_CR239","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01853-w","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Pang Y, Zhou Y, Chen J, Fu H, Guo W, Xu W, Xue X, Su G, Sun L. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. Signal Transduct Target Ther. 2024;9(1): 142.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"1851_CR240","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124526","volume":"21","author":"G Barillari","year":"2020","unstructured":"Barillari G. The impact of matrix metalloproteinase-9 on the sequential steps of the metastatic process. Int J Mol Sci. 2020;21(12): 4526.","journal-title":"Int J Mol Sci"},{"key":"1851_CR241","doi-asserted-by":"crossref","unstructured":"Kim C-H. Matrix metalloproteases in the pathogenesis of hepatocarcinoma. In: Pathophysiological aspects of proteases in cancer. AMsterdam:  Elsevier; 2025, pp 121\u2013133.","DOI":"10.1016\/B978-0-443-30098-1.00007-0"},{"issue":"5","key":"1851_CR242","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3390\/cells9051212","volume":"9","author":"E Geervliet","year":"2020","unstructured":"Geervliet E, Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells. 2020;9(5):1212.","journal-title":"Cells"},{"issue":"4","key":"1851_CR243","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.3390\/ijms24043941","volume":"24","author":"H Akk\u0131z","year":"2023","unstructured":"Akk\u0131z H. Emerging role of cancer-associated fibroblasts in progression and treatment of hepatocellular carcinoma. Int J Mol Sci. 2023;24(4):3941.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1851_CR244","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/15384047.2017.1282019","volume":"18","author":"L Liu","year":"2017","unstructured":"Liu L, Qin S, Zheng Y, Han L, Zhang M, Luo N, Liu Z, Gu N, Gu X, Yin X. Molecular targeting of VEGF\/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. Cancer Biol Ther. 2017;18(3):166\u201376.","journal-title":"Cancer Biol Ther"},{"issue":"15","key":"1851_CR245","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2217\/fon-2020-0162","volume":"16","author":"SP Hack","year":"2020","unstructured":"Hack SP, Spahn J, Chen M, Cheng A-L, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020;16(15):975\u201389.","journal-title":"Future Oncol"},{"key":"1851_CR246","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","volume":"58","author":"S Wind","year":"2019","unstructured":"Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet. 2019;58:1131\u201347.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1851_CR247","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2024.06.033","volume":"81","author":"J-W Zhang","year":"2024","unstructured":"Zhang J-W, Lai R-M, Wang L-F, Wang S-L, Xue H-X, Li C, Zheng Z-Z, Li J, Zhu Y-Y, Zeng D-W. Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B. J Hepatol. 2024;81(6):960\u201370.","journal-title":"J Hepatol"},{"key":"1851_CR248","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jvh.13150","volume":"26","author":"H Ren","year":"2019","unstructured":"Ren H, Huang Y. Effects of pegylated interferon-\u03b1 based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B. J Viral Hepat. 2019;26:5\u201331.","journal-title":"J Viral Hepat"},{"issue":"2","key":"1851_CR249","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/hep.31282","volume":"73","author":"J Chen","year":"2020","unstructured":"Chen J, Li Y, Lai F, Wang Y, Sutter K, Dittmer U, Ye J, Zai W, Liu M, Shen F. Functional comparison of IFN-alpha subtypes reveals potent HBV suppression by a concerted action of IFN-alpha and-gamma signaling. Hepatology. 2020;73(2):486\u2013502.","journal-title":"Hepatology"},{"key":"1851_CR250","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s00432-006-0091-y","volume":"132","author":"H-C Sun","year":"2006","unstructured":"Sun H-C, Tang Z-Y, Wang L, Qin L-X, Ma Z-C, Ye Q-H, Zhang B-H, Qian Y-B, Wu Z-Q, Fan J. Postoperative interferon \u03b1 treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458\u201365.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"1851_CR251","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","volume":"12","author":"B Hu","year":"2022","unstructured":"Hu B, Yu M, Ma X, Sun J, Liu C, Wang C, Wu S, Fu P, Yang Z, He Y. IFN\u03b1 potentiates anti\u2013PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov. 2022;12(7):1718\u201341.","journal-title":"Cancer Discov"},{"issue":"8","key":"1851_CR252","first-page":"367","volume":"17","author":"E Tsai","year":"2021","unstructured":"Tsai E. Review of current and potential treatments for chronic hepatitis B virus infection. Gastroenterol Hepatol. 2021;17(8):367.","journal-title":"Gastroenterol Hepatol"},{"issue":"16","key":"1851_CR253","doi-asserted-by":"publisher","first-page":"14879","DOI":"10.1007\/s00432-023-05265-1","volume":"149","author":"Y Li","year":"2023","unstructured":"Li Y, Wang C, Yin X, Jiang L, Li X, Yang J. Profile and clinical significance of interferon gamma-inducible protein-10 (IP-10) and its receptor in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149(16):14879\u201388.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"1851_CR254","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/08820139.2020.1869251","volume":"51","author":"RM Talaat","year":"2022","unstructured":"Talaat RM, Elsharnoby S, Abdelkhalek MS, El-Shenawy SZ, Elmasry S. The impact of interferon-\u03b3 (IFN-\u03b3) and IFN-\u03b3-inducible protein 10 (IP-10) genes\u2019 polymorphism on risk of hepatitis C virus-related liver cirrhosis. Immunol Invest. 2022;51(3):688\u2013704.","journal-title":"Immunol Invest"},{"issue":"3","key":"1851_CR255","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.livres.2022.08.003","volume":"6","author":"K Wang","year":"2022","unstructured":"Wang K, Gu C, Yu G, Lin J, Wang Z, Lu Q, Xu Y, Zhao D, Jiang X, Mai W. Berberine enhances the anti-hepatocellular carcinoma effect of NK92-MI cells through inhibiting IFN-gamma-mediated PD-L1 expression. Liver Res. 2022;6(3):167\u201374.","journal-title":"Liver Res"},{"issue":"1","key":"1851_CR256","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-021-00776-0","volume":"6","author":"D Wang","year":"2021","unstructured":"Wang D, Fu B, Shen X, Guo C, Liu Y, Zhang J, Sun R, Ye Y, Li J, Tian Z. Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-\u03b1 therapy. Signal Transduct Target Ther. 2021;6(1):376.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"1851_CR257","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.3390\/jpm13121675","volume":"13","author":"K Dimitriadis","year":"2023","unstructured":"Dimitriadis K, Katelani S, Pappa M, Fragkoulis GE, Androutsakos T. The role of interleukins in HBV infection: a narrative review. J Pers Med. 2023;13(12):1675.","journal-title":"J Pers Med"},{"issue":"4","key":"1851_CR258","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.7150\/ijbs.89568","volume":"20","author":"X Xin","year":"2024","unstructured":"Xin X, Cheng X, Zeng F, Xu Q, Hou L. The role of TGF-\u03b2\/SMAD signaling in hepatocellular carcinoma: from mechanism to therapy and prognosis. Int J Biol Sci. 2024;20(4):1436.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"1851_CR259","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1002\/cam4.3880","volume":"10","author":"JJ Harding","year":"2021","unstructured":"Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Benhadji KA, Kelley RK, Abou-Alfa GK. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Med. 2021;10(9):3059\u201367.","journal-title":"Cancer Med"},{"key":"1851_CR260","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.601240","volume":"10","author":"C Donisi","year":"2021","unstructured":"Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M. Immune checkpoint inhibitors in the treatment of HCC. Front Oncol. 2021;10: 601240.","journal-title":"Front Oncol"},{"issue":"1","key":"1851_CR261","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-024-00593-4","volume":"19","author":"SB Sheikhrobat","year":"2024","unstructured":"Sheikhrobat SB, Mahmoudvand S, Kazemipour-Khabbazi S, Ramezannia Z, Baghi HB, Shokri S. Understanding lactate in the development of Hepatitis B virus-related hepatocellular carcinoma. Infect Agents Cancer. 2024;19(1): 31.","journal-title":"Infect Agents Cancer"},{"issue":"3","key":"1851_CR262","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.21037\/jgo-24-368","volume":"15","author":"J Chen","year":"2024","unstructured":"Chen J, He G, Cai D, Giovannetti E, Inamura K, Liu S, Ma W. Lactic acid: a narrative review of a promoter of the liver cancer microenvironment. J Gastrointest Oncol. 2024;15(3):1282.","journal-title":"J Gastrointest Oncol"},{"key":"1851_CR263","doi-asserted-by":"crossref","unstructured":"Khan MW, Terry AR, Priyadarshini M, Guzman G, Cordoba-Chacon J, Ben-Sahra I, Wicksteed B, Layden BT. The hexokinase \u201cHKDC1\u201d interaction with the mitochondria is essential for hepatocellular carcinoma progression. bioRxiv 2021, 2021.2011.2010.468146.","DOI":"10.1101\/2021.11.10.468146"},{"issue":"1","key":"1851_CR264","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52160-x","volume":"14","author":"S Cho","year":"2024","unstructured":"Cho S, Kim W, Yoo D, Han Y, Hwang H, Kim S, Kim J, Park S, Park Y, Jo H. Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells. Sci Rep. 2024;14(1): 1751.","journal-title":"Sci Rep"},{"issue":"1","key":"1851_CR265","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-023-01780-9","volume":"22","author":"L Zhou","year":"2023","unstructured":"Zhou L, Xia S, Liu Y, Ji Q, Li L, Gao X, Guo X, Yi X, Chen F. A lipid metabolism\u2013based prognostic risk model for HBV\u2013related hepatocellular carcinoma. Lipids Health Dis. 2023;22(1): 46.","journal-title":"Lipids Health Dis"},{"key":"1851_CR266","doi-asserted-by":"crossref","unstructured":"Tan, S. L. W.; Israeli, E.; Ericksen, R. E.; Chow, P. K.; Han, W. The altered lipidome of hepatocellular carcinoma. In Seminars in Cancer Biology, 2022; Elsevier: Vol. 86, pp 445\u2013456.","DOI":"10.1016\/j.semcancer.2022.02.004"},{"key":"1851_CR267","doi-asserted-by":"crossref","unstructured":"Girisa S, Aswani BS, Manickasamy MK, Hegde M, Alqahtani MS, Abbas M, Sethi G, Kunnumakkara AB. Restoring FXR expression as a novel treatment strategy in liver cancer and other liver disorders. Expert Opin  Therapeutic Targets. 2025, (just-accepted). https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/14728222.2025.2487465","DOI":"10.1080\/14728222.2025.2487465"},{"issue":"1","key":"1851_CR268","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40170-024-00363-1","volume":"12","author":"R Shrestha","year":"2024","unstructured":"Shrestha R, Vancuylenburg CS, Beretta M, Zhou M, Shah DP, Olzomer EM, Richards SL, Hoehn KL, Byrne FL. Complete inhibition of liver acetyl-CoA carboxylase activity is required to exacerbate liver tumorigenesis in mice treated with diethylnitrosamine. Cancer & Metabolism. 2024;12(1):34.","journal-title":"Cancer & Metabolism"},{"key":"1851_CR269","unstructured":"De A, Duseja A. Current and future pharmacological treatment in NAFLD\/NASH. https:\/\/www.researchgate.net\/profile\/Arka-De\/publication\/359266398_Current_and_Future_Pharmacological_Treatment_in_NAFLDNASH_Arka_De_Ajay_Duseja\/links\/6231f6504ba65b2481351e38\/Current-and-Future-Pharmacological-Treatment-in-NAFLD-NASH-Arka-De-Ajay-Duseja.pdf"},{"issue":"7","key":"1851_CR270","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1731","volume":"14","author":"B Yue","year":"2024","unstructured":"Yue B, Gao Y, Hu Y, Zhan M, Wu Y, Lu L. Harnessing CD8+ T cell dynamics in hepatitis B virus-associated liver diseases: Insights, therapies and future directions. Clin Transl Med. 2024;14(7): e1731.","journal-title":"Clin Transl Med"},{"issue":"7","key":"1851_CR271","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/ph14070606","volume":"14","author":"A Mor","year":"2021","unstructured":"Mor A, Tankiewicz-Kwedlo A, Pawlak D. Kynurenines as a novel target for the treatment of malignancies. Pharmaceuticals. 2021;14(7):606.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"1851_CR272","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/molecules28020862","volume":"28","author":"P Pandey","year":"2023","unstructured":"Pandey P, Khan F, Upadhyay TK, Maqsood R. Review to understand the crosstalk between immunotherapy and tumor metabolism. Molecules. 2023;28(2):862.","journal-title":"Molecules"},{"issue":"18","key":"1851_CR273","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1158\/0008-5472.CAN-22-0042","volume":"82","author":"Y Li","year":"2022","unstructured":"Li Y, Li B, Xu Y, Qian L, Xu T, Meng G, Li H, Wang Y, Zhang L, Jiang X. GOT2 silencing promotes reprogramming of glutamine metabolism and sensitizes hepatocellular carcinoma to glutaminase inhibitors. Can Res. 2022;82(18):3223\u201335.","journal-title":"Can Res"},{"key":"1851_CR274","unstructured":"Hammer K. The Role of Glutamine Metabolism in Experimental and Human Intrahepatic Cholangiocarcinoma. 2024. https:\/\/epub.uni-regensburg.de\/58648\/"},{"issue":"23","key":"1851_CR275","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70224","volume":"28","author":"K Guo","year":"2024","unstructured":"Guo K, Wang T, Yin J, Yang S, Cui H, Cao Z, Zhao Q, Xie G, Lu J, Gu G. Identification of cuproptosis-related patterns predict prognosis and immunotherapy response in hepatocellular carcinoma. J Cell Mol Med. 2024;28(23): e70224.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"1851_CR276","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.14016","volume":"32","author":"I Ali","year":"2025","unstructured":"Ali I, Muhammad S, Naqvi SSZH, Wei L, Yan W, Khan MF, Mahmood A, Liu H, Shah W. Hepatitis B virus-associated liver carcinoma: the role of iron metabolism and its modulation. J Viral Hepatitis. 2025;32(4): e14016.","journal-title":"J Viral Hepatitis"},{"issue":"12","key":"1851_CR277","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3390\/v15122359","volume":"15","author":"Y Li","year":"2023","unstructured":"Li Y, Ou J-HJ. Regulation of mitochondrial metabolism by hepatitis B virus. Viruses. 2023;15(12):2359.","journal-title":"Viruses"},{"key":"1851_CR278","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2025.105781","volume":"177","author":"C Hawkins","year":"2025","unstructured":"Hawkins C, Waddilove E, Matthews PC, Delphin M. Impact of metformin on HBV replication: no evidence of suppression in vitro. J Clin Virol. 2025;177: 105781.","journal-title":"J Clin Virol"},{"issue":"7","key":"1851_CR279","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.62347\/QLHG1014","volume":"14","author":"S-Y Wu","year":"2024","unstructured":"Wu S-Y, Chen W-M, Hsu P-J, Chou T-C, Chiang M-F, Wu M-S, Lee M-C, Soong R-S. Protective effect of N-acetylcysteine against hepatocellular carcinoma in hepatitis B virus carriers. Am J Cancer Res. 2024;14(7):3639.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"1851_CR280","doi-asserted-by":"publisher","first-page":"4","DOI":"10.15406\/jhvrv.2024.11.00273","volume":"11","author":"K Kulvinder","year":"2024","unstructured":"Kulvinder K, Gautam N, Mandeep S. Targeting dysfunctional mitochondrial metabolism of hepatocytes caused hepatitis B virus (HBV) in the treatment of the chronic HBV infection\u2014a narrative review. J Hum Virol Retrovirol. 2024;11(1):4\u201312.","journal-title":"J Hum Virol Retrovirol"},{"issue":"28","key":"1851_CR281","doi-asserted-by":"publisher","first-page":"46691","DOI":"10.18632\/oncotarget.17358","volume":"8","author":"C Chen","year":"2017","unstructured":"Chen C, Lou T. Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget. 2017;8(28):46691.","journal-title":"Oncotarget"},{"issue":"4","key":"1851_CR282","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000513486","volume":"10","author":"S Qin","year":"2021","unstructured":"Qin S, Ren Z, Feng Y-H, Yau T, Wang B, Zhao H, Bai Y, Gu S, Li L, Hernandez S. Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study. Liver cancer. 2021;10(4):296\u2013308.","journal-title":"Liver cancer"},{"issue":"5","key":"1851_CR283","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.62347\/KGCL7357","volume":"14","author":"T Li","year":"2024","unstructured":"Li T, Yi J, Wu H, Wang K, Zhou B. SLC7A11 in hepatocellular carcinoma: Potential mechanisms, regulation, and clinical significance. Am J Cancer Res. 2024;14(5):2326.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"1851_CR284","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/jcm12051715","volume":"12","author":"H Su","year":"2023","unstructured":"Su H, Liu Y, Huang J. Ferroptosis-related gene SLC1A5 is a novel prognostic biomarker and correlates with immune microenvironment in HBV-related HCC. J Clin Med. 2023;12(5):1715.","journal-title":"J Clin Med"},{"key":"1851_CR285","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.879205","volume":"12","author":"Y Lan","year":"2022","unstructured":"Lan Y, Jin C, Kumar P, Yu X, Lenahan C, Sheng J. Ketogenic diets and hepatocellular carcinoma. Front Oncol. 2022;12: 879205.","journal-title":"Front Oncol"},{"key":"1851_CR286","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3389\/fimmu.2020.01037","volume":"11","author":"B Li","year":"2020","unstructured":"Li B, Yan C, Zhu J, Chen X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P. Anti\u2013PD-1\/PD-L1 blockade immunotherapy employed in treating hepatitis B virus infection\u2013related advanced hepatocellular carcinoma: a literature review. Front Immunol. 2020;11:1037.","journal-title":"Front Immunol"},{"issue":"2","key":"1851_CR287","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79(2):506\u201315.","journal-title":"J Hepatol"},{"issue":"6","key":"1851_CR288","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/biomedicines10061304","volume":"10","author":"SH Tella","year":"2022","unstructured":"Tella SH, Kommalapati A, Mahipal A, Jin Z. First-line targeted therapy for hepatocellular carcinoma: role of atezolizumab\/bevacizumab combination. Biomedicines. 2022;10(6):1304.","journal-title":"Biomedicines"},{"issue":"4","key":"1851_CR289","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A-L Cheng","year":"2022","unstructured":"Cheng A-L, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Lim HY, Kudo M, Breder V, Merle P. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"key":"1851_CR290","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2022.06.058","volume":"174","author":"CA Fulgenzi","year":"2022","unstructured":"Fulgenzi CA, D\u2019Alessio A, Airoldi C, Scotti L, Demirtas CO, Gennari A, Cortellini A, Pinato DJ. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials. Eur J Cancer. 2022;174:57\u201367.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1851_CR291","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","volume":"8","author":"H-D Zhu","year":"2023","unstructured":"Zhu H-D, Li H-L, Huang M-S, Yang W-Z, Yin G-W, Zhong B-Y, Sun J-H, Jin Z-C, Chen J-J, Ge N-J. Transarterial chemoembolization with PD-(L) 1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8(1):58.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"1851_CR292","doi-asserted-by":"publisher","first-page":"8669","DOI":"10.1007\/s00330-023-09754-2","volume":"33","author":"Z-C Jin","year":"2023","unstructured":"Jin Z-C, Zhong B-Y, Chen J-J, Zhu H-D, Sun J-H, Yin G-W, Ge N-J, Luo B, Ding W-B, Li W-H. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study. Eur Radiol. 2023;33(12):8669\u201381.","journal-title":"Eur Radiol"},{"issue":"1","key":"1851_CR293","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","volume":"5","author":"J Choi","year":"2019","unstructured":"Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim Y-S. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019;5(1):30\u20136.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1851_CR294","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","volume":"77","author":"M-F Yuen","year":"2022","unstructured":"Yuen M-F, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, Thompson AJ, Given BD, Schluep T, Hamilton J. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol. 2022;77(5):1287\u201398.","journal-title":"J Hepatol"},{"issue":"3","key":"1851_CR295","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","volume":"65","author":"AS Lok","year":"2016","unstructured":"Lok AS, Pan CQ, Han S-HB, Trinh HN, Fessel WJ, Rodell T, Massetto B, Lin L, Gaggar A, Subramanian GM. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 2016;65(3):509\u201316.","journal-title":"J Hepatol"},{"issue":"8","key":"1851_CR296","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/cells10081917","volume":"10","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S. Familiarity breeds strategy: in silico untangling of the molecular complexity on course of autoimmune liver disease-to-hepatocellular carcinoma transition predicts novel transcriptional signatures. Cells. 2021;10(8):1917.","journal-title":"Cells"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01851-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01851-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01851-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:02:50Z","timestamp":1771336970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01851-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":296,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1851"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01851-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"148"}}